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Jerry Vockley, MD, PhD 
ABSTRACT 
Medium chain acyl-CoA dehydrogenase deficiency (MCADD) is a common biochemical genetic 
disorder in the US. Nearly 90% of alleles from MCADD patients contain a common mutation in 
the ACADM (c.985A>G). The change replaces a lysine with a glutamate (K304E), causing 
improper folding. The K304E protein can fold to a mature form and is then stable and active 
when expressed in a prokaryotic system with molecular chaperonins. The goal of this project was 
to identify chemical chaperones capable of stabilizing the K304E MCAD protein. Since even a 
small amount of MCAD activity restores metabolic flux, inducing intra-mitochondrial folding of 
K304E MCAD has the potential to be protective for patients. To demonstrate proof of principle, 
dimethylsulfoxide, glycerol, betaine, trimethylamine N-oxide (TMAO), and L-proline were tested 
for the ability to increase MCAD activity in lymphoblasts having c.985G>A alleles. TMAO and 
glycerol significantly increased MCAD activity in these cells. Phenylbutyrate is converted to its 
CoA ester form and metabolized to phenylacetyl-CoA through β-oxidation initiated by MCAD. 
As a substrate analogue for MCAD, phenylbutyryl-CoA is expected to improve protein stability. 
Experiments in HEK293 cells containing inducible wild type or K304E MCAD alleles, 
phenylbutyrate increased wild type MCAD activity by 30% and K304E MCAD activity by 154%. 
A clinical trial testing the efficacy of phenylbutyrate in MCAD patients is underway. Drug 
targeting sites were also investigated using molecular modeling. The docking site for electron 
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transfer flavoprotein (ETF) was hypothesized to be a viable site. Twelve amino acid peptides 
with variable sequences were synthesized based on ETF βArg191-βLys202. One of the peptides 
significantly increased thermal stability of K304E MCAD. Circular dichroism spectroscopy 
confirmed binding of the synthetic peptide, inducing a shift in the Tm of the enzymes. The ETF 
docking peptide analogue also protected K304E MCAD protein against limited proteolysis by 
Staphylococcus aureus V8. These results confirm that ETF docking site is a viable target for 
MCADD. 
PUBLIC HEALTH SIGNIFICANCE: Even though newborn screening has reduced the 
mortality of the MCADD, patients still require frequent hospital visits during metabolic 
decompensation. New treatments for MCADD will significantly reduce the burden of disease on 
these patients. 
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1.0  INTRODUCTION 
1.1 BIOGENESIS OF MITOCHONDRIAL PROTEINS 
1.1.1 General characteristics of mitochondrial proteins  
Mitochondria are unique double membrane-bound (the outer membrane and the inner 
membrane) organelles that are involved in several major cellular functions such as energy 
generation, amino acid metabolism, apoptosis, etc. Most of the mitochondrial proteins are 
encoded in the nucleus. About 15% of the nuclear genes are encoding mitochondrial proteins 
(Neupert and Herrmann, 2007). These genes are transcribed in the nucleus, the proteins are 
synthesized in the cytosol as precursor forms, and transported into mitochondria by different 
protein translocases in the outermembrane. Receptors on the surface of mitochondria can 
recognize mitochondrial targeting signals from the proteins and then import these proteins. There 
are different targeting signals that can determine the final localization of each protein. Some 
inner membrane proteins have N-terminus cleavable sequences and others have internal 
sequences. Using different prediction programs, these targeting sequences can easily be 
identified (Table 1). Molecular chaperones in mitochondria are known to help the proper folding 
of these proteins. Quality control proteases degrade the unfolded proteins in the mitochondria. 
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Table 1. Prediction for matrix-targeting sequences 
Name Internet address Organization 
TargetP 1.1 Server http://www.cbs.dtu.dk/services/TargetP/ Technical University of 
Denmark 
PSORT WWW server http://psort.hgc.jp/ University of Tokyo, Japan 
MITOPROT http://ihg.gsf.de/ihg/mitoprot.html Helmholtz Center Munich 
INRA https://urgi.versailles.inra.fr/predotar/predotar.html Unité de Recherche en 
Génomique Végétale  
 
There are different classes of mitochondrial membrane proteins that are located in outer 
membrane or inner membrane of mitochondria.  Figure 1 shows the different mitochondrial 
membrane proteins. Proteins with β-barrel trans membrane domains are typical forms of 
mitochondrial outer membrane proteins such as Tom40, Sam50, or Porin (Figure 1a). Other 
proteins with a single or multiple α-helical transmembrane segments are also known to be 
involved in the outer membrane of mitochondria. Mitochondrial inner membrane proteins can be 
classified by the type and position of the signal sequences (Figure 1b). Many mitochondrial inner 
membrane proteins have presequences that will be cleaved after getting into the mitochondrial 
matrix.   
 2 
 Figure 1. Major classes of mitochondrial membrane proteins 
(a) Mitochondrial outer membrane proteins. Typical forms of mitochondrial outer membrane proteins have a β-
barrel transmembrane domain. Some proteins have a single α-helical transmembrane segment and others have 
multiple α-helical transmembrane segments (polytopic membrane proteins).  (b) Mitochondrial inner membrane 
proteins. Mitochondrial inner membrane proteins are classified based on the presence of N-terminal presequences 
and the number of α-helical transmembrane segments.  
1.1.2 The protein import machinery of mitochondria 
There are three main translocation complexes in mitochondria, TOM (translocase of the 
outer membrane), TIM23 (translocase of the inner membrane 23) and TIM22 (translocase of the 
inner membrane 22). The TOM complex is localized in the outer membrane and regulates the 
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import of all the proteins into mitochondria. The TOM complex is composed of two main groups 
of subunits: receptor subunits (Tom70, Tom22 and Tom20) and membrane-embedded subunits 
(Tom40, Tom7, Tom6, and Tom5). The receptor subunits have binding sites for precursor 
proteins in the cytosol and membrane-embedded subunits form the translocation pore that 
proteins in the cytosol can be transported into mitochondria inner membrane space (Figure 2).  
The TOM complex is also known to act as a molecular chaperone. 
 
 
 Figure 2. The TOM complex  
The Tom (translocase of the outer membrane) complex is composed of surface receptors (Tom70, Tom22, and 
Tom20) and translocation pore (Tom40, Tom7, Tom6, and Tom5).  
 
The TIM 23 and TIM22 complexes are located in the inner membrane. TIM23 complex 
can import the presequence containing preproteins and TIM22 complex can import the precursor 
proteins having internal targeting signals. Presequences are positively charged amphipathic α-
helical segments and usually composed of about 15 to 55 amino acids (Vogtle et al., 2009).  
Two major complexes, TIM23 and TIM22, are known to be involved in the transport of 
the proteins from the intermembrane space into mitochondrial matrix (Figure 3 and 4). In both 
cases, the electrical membrane potential changes are the key driving force for transporting 
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proteins into the matrix. TIM23 complex is composed of different proteins that are related to the 
interaction of the proteins in the intermembrane space and the import motor.  
 
Figure 3. The TIM23 complex 
The TIM23 complex is composed of membrane sectors (Tim50, Tim23, Tim21, and Tim17) and import motors 
(Tim44, Tim16/Pam16, Tim14/Pam18, mtHsp70, and Mge1). Membrane sectors are exposed to the intermembrane 
space. Especially, Tim17 and Tim23 form the translocation channel. The import motors are exposed to matrix.  
 
 
 
 
 
 Figure 4. The TIM22 complex  
TIM22 complex is composed of Tim54, Tim22, and Tim18. TIM22 translocase transports the substrate proteins by 
electrical membrane potential changes.  
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1.2 MITOCHONDRIAL Β-OXIDATION 
1.2.1 Mitochondrial fatty acid β-oxidation 
Mitochondrial fatty acyl-CoA β-oxidation (FAO) is a major source of energy-generating 
reducing equivalents during stress and fasting and provides ~80% of energy for the heart even 
under non-stress conditions (Rinaldo et al., 2002; Shekhawat et al., 2005). FAO is comprised of 
two main steps: 1) import of activated fatty acids into mitochondria and 2) β-oxidation of the 
acyl-CoA substrates by sequential removal of two carbon acetyl-CoA units (Bartlett and Eaton, 
2004).  
Energy is harvested from this process in two ways. First, reducing equivalents from the 
FAO enzymatic reactions can enter the mitochondrial respiratory chain directly. Second, acetyl-
CoA can enter the tricarboxylic acid cycle (TCA, also known as the Kreb cycle), which in turn 
generates additional reducing equivalents for oxidative phosphorylation. Acetyl-CoA can also 
lead to the generation of ketone bodies, an important alternative energy source for the brain 
during fasting. Figure 5 shows the overall process of the import of fatty acids into the 
mitochondria.  
First, carnitine transporters transport carnitines from the extracellular space into the 
cytosol. Carnitine (β-hydroxy-ϒ-trimethylaminobutyric acid) transports long chain fatty acids 
into the mitochondria. When the intracellular concentrations of malonyl-CoA is reduced due to 
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fasting, carnitine palmitoyl transferase I (CPT I) is upregulated. Fatty acids are converted into 
acyl-CoA and to acyl carnitines, which are transported across the inner mitochondrial membrane 
by carnitine:acylcarnitine translocases (CACT). Once these acylcarnitines reach the inner 
mitochondrial matrix, they are converted again into acyl-CoA esters by carnitine palmitoyl 
transferase II (CPT II). Free carnitines are recycled and returned to the cytoplasm. 
 
 
Figure 5. Transport of fatty acids into mitochondria  
Detailed explanations in text. 
 
Once the fatty acids get into the mitochondrial matrix, β-oxidation will occur. Figure 6 
shows the mitochondrial β-oxidation spiral. In each step, two carbons are removed. The first step 
of this process is by acyl-CoA dehydrogenases (ACDs). ACDs move pro-R-α-hydrogen and the 
pro-R-β-hydrogen from the acyl-CoA to the N-5 position of flavin. As a final product of FAO, 
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acetyl-CoA will be generated. In liver, acetyl-CoA will be a source of ketone bodies. Since 
ketone bodies are important energy source for brain, generation of ketone bodies is critical for 
the body when body has high-energy demands. And in heart and skeletal muscle, acetyl-CoA 
esters will enter TCA cycle and be used in energy generation. Especially in mitochondria, FAO 
can generate ketone bodies that are a useful alternative energy source for the brain.  
 
Figure 6. Mitochondrial matrix β-spirals  
Detailed explanations in text. 
 
1.2.2 Mitochondrial FAO disorders 
Most of the FAO disorders (FAOD) are inherited as autosomal recessive traits. Mutations 
in genes related to fatty acid transport and fatty acids oxidation cause FAOD. Depending on the 
function of the mutant gene, intermediate forms of fatty acids or abnormal proteins can 
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accumulate and downstream products that can be the major sources of energy generation in the 
body can be depleted. Therefore, the clinical symptoms of mitochondrial FAOD are related to 
the loss of function of enzyme activity, accumulation of abnormal enzymes, or accumulation of 
upstream fatty acids, etc. Ketone bodies, products of the mitochondrial FAO, are major energy 
sources especially for cardiac muscle, kidneys, and the brain. Thus, FAOD can sometimes lead 
into serious conditions such as sudden death. The clinical symptoms of these diseases vary from 
mild to severe such as severe metabolic acidosis, hypoglycemia, lethargy, hyperammonemia, 
cardiomyopathy, liver failure, comma or even sudden death (Shekhawat et al., 2005). In case of 
late onset FAOD, the symptoms are episodic myopathy, neuropathy, or retinopathy. Prolonged 
fasting, viral infection, acute illness, strenuous physical activity, or any physiological stresses 
can trigger the clinical symptoms of these disorders. The clinical phenotype of each FAO 
disorders and the biochemical characteristics are shown in table 2. 
 
Table 2. Mitochondrial fatty acid oxidation disorders  
Enzyme deficiency Gene Clinical phenotype Laboratory findings 
Carnitine transporter OCTN2 Cardiomyopahty, 
skeletal myopathy, 
sudden death 
Decreased total and free 
carnitines 
Long-chain fatty acid 
transporter 
FATP1-6 Acute liver failure in 
childhood requiring liver 
transplantation 
Reduced intracellular C14-C18 
fatty acids, 
reduced fatty acid oxidation 
Carnitine palmitoyl 
transferase-I 
CPT-I Liver failure, skeletal 
myopathy, and sudden 
death 
Normal or increased free 
carnitine 
Carnitine translocase  CACT Chronic progressive liver 
failure 
Normal or decreased free 
carnitine,  
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abnormal acylcarnitine profile 
Carnitine palmitoyl 
transferase-II 
CPT-II Liver failure,  
cardiomyopathy 
Normal or decreased free 
carnitine,  
abnormal acylcarnitine profile 
Short-chain acyl CoA 
dehydrogenase 
SCAD Benign to a severe 
presentation including 
encephalopathic disease 
to progressive myopathy 
Normal or decreased free 
carnitine,  
Inconsistently abnormal 
acylcarnitine profile 
Medium-chain acyl 
CoA dehydrogenase 
MCAD Hypoglycemia, sudden 
death 
Increased plasma C6-C10 free 
fatty acid, in creased C8-C10 
acyl-carnitine 
Very long-chain acyl 
CoA dehydrogenase 
VLCAD Dilated cardiomyopathy, 
hypoglycemia 
Increased C14:1 and C14 
acylcarnitine, 
Increased plasma C10-C16 free 
fatty acids 
ETF dehydrogenase ETF-DH Nonketotic fasting 
hypoglycemia 
Increased acyl-carnitine 
Electron transport 
flavoprotein-α 
α-ETF Nonketotic fasting 
hypoglycemia 
Increased acyl-carnitine 
Electron transport 
flavoprotein-β 
β-ETF Fasting hypoglycemia Increased acyl-carnitine 
Short-chain L-3-
hydroxyacyl CoA 
dehydrogenase 
SCHAD Hypoglycemia Decreased free carnitine, 
elevated free fatty acids, 
abnormal urine organic acid and 
plasma acylcarnitines 
Long-chain L-3-
hydroxyacyl CoA 
dehydrogenase 
LCHAD HELLP syndrome Decreased free fatty acids, 
increased C16-OH and C18-OH 
carnitines 
Mitochondrial 
trifunctional protein 
MTP Severe cardiac and 
skeletal myopathy,  
hypoglycemia 
Decreased free carnitine, 
increased C16-OH and C18-OH 
carnitines 
Table 2 Continued 
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Long-chain 3-
ketoacyl-CoA 
thiolase 
LKAT Severe neonatal 
presentation, 
hypoglycemia 
Increased 2-trans, 4-cis 
decadienoylcarnitine 
2,4-Dienoyl-CoA 
reductase 
DECR1 Hypotonia in the 
newborn 
Increased acyl to free carnitine 
ratio 
HMG-CoA 
synthetase 
HMGCS2 Hypoketosis Elevated total plasma fatty acids 
HMG-CoA lyase HMGCL Hypoketosis Increased C5-OH, and 
methylglutaryl-carnitine 
 
1.2.3 The use of mouse models in mitochondrial fatty acid oxidation disorders 
Mouse models are useful tools to study FAOD. Mice with mutations in FAOD genes may 
present similar clinical symptoms to human patients, and are used to investigate the mechanisms 
and pathophysiology of the FAOD. The major phenotypes of these mouse models are carnitine 
depletion, lethality in early gestation or neonatal deaths, cold intolerance, etc. However, since 
currently available mouse models have null alleles, it is difficult to study the effect of certain 
missense mutations, or therapies specifically targeting common mutations for FAOD due to the 
complete lack of ACD expression. Also, some mutations show lethality in early gestation in 
homozygous animals. Therefore, those models also have some difficulties related to further 
studies in heterozygotic models. Table 3 shows the enzyme deficiencies and phenotypes of 
currently available mouse models.  
 
 
 
Table 2 Continued 
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Table 3. Mouse models of mitochondrial β-oxidation of fatty acid disorders  
Enzyme deficiency Mouse phenotype 
Carnitine palmitoyl-CoA transferase-1a  
(liver isoform) 
Normal phenotype 
Homozygous lethal in early gestation 
Carnitine palmitoyl-CoA transferase-1b 
(muscle isoform) 
Normal phenotype 
Homozygous lethal in early gestation 
Very-long-chain acyl-CoA dehydrogenase 
deficiency: two independent mouse models 
Cardiac phenotype 
Hepatic and myopathic phenotypes after stress 
Long-chain acyl-CoA dehydrogenase 
deficiency 
Sudden death 
Fatty change of liver and heart 
Medium-chain acyl-CoA dehydrogenase 
deficiency 
Neonatal death 
Fasting and cold intolerance 
Mitochondrial trifunctional protein  
(TFP α-subunit) deficiency 
Neonatal hypoglycemia 
Fatty change of liver 
Mitochondrial trifunctional protein 
(TFP β-subunit) deficiency 
Viable 
Medium/short-chain 3-hydroxyacyl-CoA 
dehydrogenase deficiency 
Fasting and cold intolerance with development 
of fatty liver and kidney 
Short-chain acyl-CoA dehydrogenase 
deficiency 
Fasting and cold intolerance with development 
of fatty liver and kidney 
 
1.3 ACYL-COA DEHYDROGENASES 
1.3.1 Acyl-CoA dehydrogenase gene family  
The acyl-CoA dehydrogenases (ACADs) are a family of evolutionarily conserved nuclear 
encoded flavoenzymes active in mitochondrial β-oxidation and branched chain amino acid 
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metabolism (Ghisla and Thorpe, 2004; Kim and Miura, 2004; Swigonova et al., 2009). Unlike 
most cellular dehydrogenases, the ACADs use a protein as their electron acceptor, the electron 
transfer flavoprotein (ETF), which then transfers its electrons to the electron transfer chain 
through ETF dehydrogenase (ETFDH, also known as ETF:ubiquinone oxidoreductase). Five 
ACADs (VLCAD, LCAD, ACAD9, MCAD, and SCAD) are involved in the first step of 
mitochondrial fatty acid β-oxidation. These enzymes are structurally homologous, but each 
enzyme has a characteristic pattern of substrate utilization. Mutations in all but LCAD have been 
identified in patients, and each deficiency can present with large spectrum of symptoms. MCAD 
deficiency is the most common of these disorders with a frequency of 1:10,000-1:20,000 births 
in the US, with the highest incidence in Caucasians of Western European origin.  
Each of these proteins are encoded in the nucleus and are located in mitochondria or 
peroxisome. The ACAD family has 11 known members, namely, SCAD, MCAD, LCAD, 
VLCAD, ACAD9, ACAD10, ACAD11, i2VD, i3VD, iBD, and GCDH.  Five members (SCAD, 
MCAD, LCAD, VLCAD, and ACAD9) are involved in fatty acid β-oxidation. And four 
members (i2VD, i3VD, iBD, and GCD) are involved in amino acid metabolism. Table 4 
summarizes the characteristics of each ACD (Kim and Miura, 2004). 
 
Table 4. Acyl-CoA dehydrogenases 
Abbreviations Full name Pathway Location Target fatty 
acids/ 
amino acids 
Active form 
SCAD Short-chain acyl-CoA 
dehydrogenase 
Fatty acid 
β-oxidation 
12q24.31 C4 and C6 Homotetramer 
MCAD Medium-chain acyl-CoA 
dehydrogenase 
Fatty acid 
β-oxidation 
1p31 C4 to C12 Homotetramer 
LCAD Short-chain acyl-CoA Fatty acid 2q34 C8 to C20 Homotetramer 
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dehydrogenase β-oxidation 
VLCAD Very long-chain acyl-CoA 
dehydrogenase 
Fatty acid 
β-oxidation 
17q13.1 C12 to C24 Homodimer 
ACAD9 Acyl-CoA dehydrogenase 9 Fatty acid 
β-oxidation 
3q21.3 C12 to C24 Homodimer 
ACAD10 Acyl-CoA dehydrogenase 10 Unknown 12q24.12 Unknown  Unknown 
ACAD11 Acyl-CoA dehydrogenase 11 Unknown  3q22.1 Unknown Unknown 
I2VD 
(SBCAD) 
iso(2)valery-CoA 
dehydrogenase 
short/branched-chain acyl-
CoA dehydrogenase 
Amino acid 
oxidation 
10q26.13 Isoleucine Homotetramer 
I3VD 
(IVD) 
iso(3)valery-CoA 
dehydrogenase 
isovaleryl-CoA 
dehydrogenase 
Amino acid 
oxidation 
15q14-
15q 
Leucine Homotetramer 
IBD Isobutyryl-CoA 
dehydrogenase 
Amino acid 
oxidation 
11q25 Valine Homotetramer 
GCDH Glutaryl-CoA dehydrogenase Amino acid 
oxidation 
19p13.2 Lysine and 
tryptophan 
Homotetramer 
 
ACADs share 35-45% amino acid sequence homology. As expected from the amino acid 
sequence homologies, the overall ACAD structures are similar to each other (Kim and Miura, 
2004). Also the substrate binding site of the ACADs are conserved. However, each enzyme has 
different substrate specificity and tissue expression profiles. Evolutionary study of ACADs 
enzymes showed that ACADs share the common ancestors and this implies to have important 
role in metabolism (Swigonova et al., 2009). Figure 7 shows the optimal substrates of ACADs. 
Also, there are some proteins that share a more limited homology with ACAD. The functions of 
these proteins include acyl-CoA oxidation, antibiotic biosynthesis, and even stress responses 
(Ghisla and Thorpe, 2004). Thus, ACDs and their homologs are important in a range of cellular 
functions. 
Table 4 Continued 
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Figure 7. Optimal substrates of each ACD 
CX: Each number indicates the length of the acyl-CoA chain. C14:1 indicates the unsaturated fatty acid with one 
double bond. R indicates straight alkyl chain. SCAD, MCAD, LCAD, VLCAD, and ACD9 are involved in fatty acid 
β-oxidation.  
 
SCAD Butyryl-CoA (C4) 
S 
CoA 
S 
CoA 
O 
 
FAD FADH2 
O 
MCAD Octanoyl-CoA (C8) 
S 
CoA 
S 
CoA 
O 
 
FAD FADH2 
O 
LCAD Myristoyl-CoA (C14) 
S 
CoA 
S 
CoA 
O 
 
FAD FADH2 
O 
VLCAD Palmitoyl-CoA (C16) 
S 
CoA 
S 
CoA 
O 
 
FAD FADH2 
O 
ACAD9 Palmitoleoyl-CoA (C14:1) 
S 
CoA 
S 
CoA 
O 
 
FAD FADH2 
O 
R 
R 
R 
R 
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The main function of ACADs is to transfer electrons from CoA esters to the electron 
transfer flavoprotein (ETF).  ETF dehydrogenase will transfer these electrons to the respiratory 
chain to finally generate energy through ETF dehydrogenase, a CoQ. Mutations in these enzyme 
cause fatty acid oxidation deficiencies with different spectrum of phenotypes. Out of all these 
enzymes, MCAD is the most intensively investigated, but the functions of ACAD10 and 
ACAD11 are still unknown.   
1.3.2 Mechanism of ACDs 
The ACDs use ETF as an electron acceptor in α,β-dehydrogenation. After accepting 
electrons from ACDs, ETF transfers the electrons to ETF dehydrogenase (ETFDH), and then the 
electrons will be delivered to respiratory chain (Figure 8).  
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 Figure 8. Acyl-CoA dehhydrogenases and their interaction with ETF in the α,β-dehydrogenation of acyl-
thioesters 
The enzymes involved in fatty acid β-oxidation are removing even numbered straight chains. ETF works as an 
electron acceptor of these dehydrogenases and then ETF dehydrogenase (ETFDH) delivers the electron to the 
respiratory chain.  
 
 
Figure 9 shows the α,β-dehydrogenation by MCAD protein and an active catalytic site at 
Glu 376. Glu 376, catalytic residue, plays an important role in the initial step of dehydrogenation 
(Bross et al., 1999). The α-proton from the acyl-CoA substrate is abstracted by Glu 376 and Glu 
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376-COO-, catalytic residue, interacts with FAD-2’OH and forming hydrogen bonds. The 
reduced flavin (FADH2) is reoxidized through electron transfer flavoprotein (ETF). 
 
                                                                                                        
 
Figure 9. Reaction mechanism of the α,β-dehydrogenation by MCAD 
A schematic presentation of dehydrogenation by MCAD. The active site Glu376 forms hydrogen bond with FAD 
and the substrate thioester carbonyl group. Rib indicates the ribityl side chain of the isoalloxazine. 
 
1.4 MEDIUM CHAIN ACYL-COA DEHYDROGENASE DEFICIENCY IN 
HUMANS 
1.4.1 General characteristics of MCADD 
MCADD (OMIM 201450) is one of the most common inborn errors of metabolism in 
humans, and the most common FAOD. Prior to the advent of expanded newborn screening by 
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tandem mass spectrometry (MS:MS), the clinical presentation was extremely variable with onset 
of symptoms from neonates to adulthood. Some individuals have even remained asymptomatic 
lifelong. Most frequently MCADD presented between 18-36 months of life with fasting, or 
illness induced vomiting, hypoketotic hypoglycemia, and lethargy progressing to coma and 
seizures (Iafolla et al., 1994; Vockley and Whiteman, 2002; Wanders et al., 1999).  Acutely ill 
individuals showed elevated blood concentrations of C8 (octanoyl)-carnitine together with lesser 
elevations of the C6 (hexanoyl)-, C10 (decanoyl)-, and C10:1 (decenoyl)- acylcarnitines (Duran 
et al., 1988). Approximately half of patients were not diagnosed during their initial presentation 
and half were diagnosed after having died. Fortunately, today diagnosis through clinical 
symptoms is rare as the disorder is readily identified through newborn screening by MS:MS. 
Patients thus identified are typically well, though at risk for hypoglycemia with recurrent illness 
and may require hospitalization for intravenous glucose administration. Current treatment for 
MCADD is simply to avoid fasting, and to reduce the dietary fat intake. The utility of carnitine 
supplementation is controversial.  
 
1.4.2 Molecular genetics of MCADD 
The ACADM gene, acyl-CoA dehydrogenase, C-4 to C-12 straight chain, is located on 
chromosome 1p31 and has 12 exons (Zhang et al., 1992). This gene encodes a 421-amino acid 
protein, the MCAD protein, with mitochondrial leader sequence. The MCAD mRNA is 
translated in the cytoplasm, and then the precursor protein is targeted to mitochondria, imported, 
folded to the mature subunit configuration, and assembled into a final homotetrameric active 
enzyme. Mutations in the ACADM gene can affect any of these steps, and lead to reduced 
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enzyme activity. Figure 10 shows the ACADM gene mutations identified in patients and screened 
newborns (Gregersen et al., 2008).  The introduction of NBS led to the discovery of different 
kinds of mutations in the ACADM gene. Greater than 80 variants have been identified, and one 
mutation 985A>G (K304E MCAD protein) represents almost 90% of alleles in MCADD 
patients, especially predominating in Northern European populations (Blois et al., 2005; Matern 
and Rinaldo, 1993; Smith et al., 2010). A recent study confirmed that the frequency of the 
K304E mutation is significantly higher in individuals of Northern European descent (Leal et al., 
2013). Expanded newborn screening (NBS) has led to the identification of additional novel 
mutations, but 985A>G remains the most prevalent disease causing mutation (Ensenauer et al., 
2005b; Rhead, 2006; Smith et al., 2010).  
 
 
Figure 10. Spectrum of gene variations in the ACADM gene 
The mutations found in screened newborns as MCADD.  
 
1.4.3 MCAD structure and interaction with ETF 
All ACADs except VLCAD and ACAD9 are active as homotetramers in the 
mitochondria matrix. VLCAD and ACAD9 are dimers with an extra C-terminus domain that 
occupies the space of the missing dimer in the other ACADs. The molecular mass of the 
precursor MCAD subunit is 44kDa. The N-terminal mitochondrial signal peptide is 25 amino 
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acid residues in length. After translation in the cytoplasm, it is imported into the mitochondria 
and the mitochondrial signal peptide is cleaved. The mature homotetramer includes FAD as a 
cofactor, catalyzes the first step in β-oxidation, and utilizes ETF as an electron acceptor (Matern 
and Rinaldo, 1993; Matsubara et al., 1992). X-ray crystallography studies have shown that the N-
terminal and C-terminal regions of the MCAD protein consists of densely packed α-helices that 
shape the core of the tetramer (Kim et al., 1993; Kim and Wu, 1988). The middle domain has 
two orthogonal β-sheets located at the surface of the molecule. The MCAD tetramers are 
composed of a dimer of dimers. Figure 11 shows ribbon diagrams of the MCAD monomer and 
tetramer (Kim and Miura, 2004). Substrate binding to MCAD protein does not make significant 
conformational changes. However, there are significant changes at the residues that are located 
in the active site cavity, especially at Glu 376, a catalytic residue, Tyr 375 and Glu 99. When 
substrates are not bound, water molecules can fill the active site cavity and when the medium 
chain fatty acids approaches, the water molecules are displaced.  
                                        
Figure 11. Ribbon structures of the MCAD protein 
This represents the ribbon structures of the MCAD protein. Each color (magenta, red, green, and cobalt) indicates 
the monomer of the MCAD protein.  
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1.4.4 The common MCAD mutation leads to protein misfolding 
MCAD mRNA is translated in the cytoplasm, and then the precursor protein is targeted to 
mitochondria, imported, folded to the mature subunit configuration, and assembled into a final 
homotetrameric active flavoenzyme. The K304E MCAD mutation has been shown to impair 
folding and assembly of the MCAD protein (Bross et al., 1995; Yokota et al., 1992). The 
positively charged lysine at position 304 is located in the middle of the α-helix H. Two 
negatively charged aspartates at positions 300 and 346 are close to position 304 and are known to 
interact with each other. Therefore, the positively charged lysine at position 304 replaced with a 
negatively charged glutamic acid presumably affects the balance of charges in the 
supersecondary and tertiary structure of the MCAD monomer. In patient fibroblasts, upon import 
into mitochondria, the K304E MCAD protein remains associated with the protein folding 
HSP60/10 complex, and then it is degraded. In a prokaryotic expression system, the K304E 
MCAD protein aggregates and leads to cellular death unless the bacterial chaperonin proteins, 
GroEL/ES (HSP 60/10 homologues) are co-expressed (Bross et al., 1993). In the latter case, the 
K304E MCAD protein is stabilized, correctly folded, and most importantly, is active. These 
results suggest that stabilization of the K304E MCAD protein could allow formation of 
sufficiently active enzyme to significantly impact disease phenotype.  
1.4.5 The interaction between ETF and MCAD protein 
Human electron transfer flavoprotein (ETF), the physiological electron acceptor that 
reoxidizes reduced MCAD, is a heterodimer, composed of α and β subunits, where the α subunit 
contains one FAD (Bross et al., 1999; Chohan et al., 2001; Parker, 2003a, b; Roberts et al., 1996). 
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The ETF has two main binding pocket areas; the recognition loop, an anchor site for the 
ETF:MCAD interaction, and FAD domain, a site for FAD binding. Unlike other electron carriers, 
ETF has a recognition peptide that the MCAD protein can dock to. The crystal structure of an 
ETF:MCAD complex has been solved (Figure 12) (Roberts et al., 1996; Toogood et al., 2004; 
Toogood et al., 2005). Also, Parker suggested that a single arginine residue is required for the 
interaction of ETF and MCAD protein (Parker, 2003a, b).  
 
Figure 12. Ribbon representation of MCAD:ETF complex (PDB:2A1T) 
MCAD monomers are shown in different colors (a in white, b in yellow, c in orange, and d in red). 
The α-subunit of ETF is shown in magenta and β-subunit is shown in blue.  
1.4.6 MCADD mouse model 
An MCAD deficient mouse model was generated by Tolwani et al. By using gene 
targeting, the authors deleted 1.3 kb region of exon 10 and flanking sequences. After generating 
gene-targeted embryonic stem cell clones, these clones were injected into B6 blastocysts and 
then backcrossed to both 129P2 and B6. Finally MCADD mice were generated on a B6/129 
mixed background. Clinical phenotypes of MCADD mice are similar to human MCADD. 
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MCADD mice show organic aciduria, fatty liver, and significant cold intolerance at 4°C in 
fasting conditions. Also they have high neonatal mortality rates. This model helps to understand 
the pathogenesis of MCADD.  
 
1.4.7 MCAD activity assays 
The MCAD activity can be measured from different cell types including fibroblasts and 
lymphoblasts or different tissues such as liver, heart, and skeletal muscle. There are different 
methods to detect the MCAD activity. In 1985, Frerman and Goodman developed the ETF assay 
to detect ACD activity (Frerman and Goodman, 1985). Since ETF is an electron acceptor of 
MCAD protein, ETF assay can directly detect the MCAD activity by measuring the 
stoichiometric reduction of ETF to ETFH2 using fluorometry. This is the most sensitive test 
method to detect MCAD activity. However, since ETF protein is not commercially available, the 
ETF should be purified from pig liver which process is cumbersome. And this assay requires 
anaerobic condition that is another limitation of this method to be applied in different settings. 
Dye reduction assays are different ways to measure the MCAD activity. Since ETF is a limiting 
factor, dye reduction assays are using artificial electron acceptors such as dichlorophenol 
indophenol (DCIP) or ferricenium ions. In case of DCIP assay, phenazine methosulphate (PMS) 
will be a primary electron acceptor and then DCIP will accept the secondary electrons. The 
changes of the electrons will be measured by spectrophotometer at 600nm. In case of ferricenium 
assay, ferricenium hexafluorophosphate will be used as an electron acceptor (Lehman et al., 
1990). However, these dye reduction assays are not as sensitive as ETF assay.  
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1.5 THERAPEUTIC APPROACHES FOR MCADD BY USING SMALL 
CHEMICAL CHAPERONES 
1.5.1 Use of small chemicals and/or pharmacological chaperones as drugs in human 
protein misfolding diseases 
Protein misfolding has been demonstrated as a common outcome of amino acids 
substitutions occurring at positions important for structure. Misfolding of protein promotes 
premature degradation of the protein (loss of function), the formation of toxic aggregates, and/or 
incorporation of toxic conformations into structures (gain of function) (Gregersen et al., 2005). 
Parkinson’s disease, α-1-antitrypsin deficiency, familial neurohypophyseal diabetes insipidus are 
examples of the latter mechanism, while mutations in many inborn errors of metabolism have 
demonstrated the former (Barral et al., 2004; Gregersen et al., 2005; Gregersen et al., 2006). In 
case of mutations leading to degradation of protein and loss-of-function, an increase of mutant 
protein can have two effects. The first, an increase in at least partially active protein and rescue 
of function, is the desired outcome. Unfortunately, the second possibility is stabilization of a 
mutant protein that then aggregates and generates unintended gain of function toxicity. For the 
common K304E MCAD mutation, overexpression in a prokaryotic system in conjunction with 
the bacterial chaperonin proteins GroEL/ES leads to improved folding and rescue of activity. 
While the use of molecular chaperones such as the eukaryotic GroEL/ES homologous, HSP60/10 
as therapeutic molecules would be challenging, development of small molecule chemicals as 
chaperones would be appear to be ideal potential drugs for this disease. The attractiveness of this 
approach is enhanced by the recognition from newborn screening studies that MCAD mutations 
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leaving very low levels of activity are sufficient to prevent the development of symptoms (Smith 
et al., 2010). 
Chemical chaperones are small molecular weight compounds that promote the folding of 
proteins by altering the local chemical environment or stabilize their favorable conformation 
(i.e., without direct binding). They are used extensively in vitro to enhance stability of proteins in 
storage (glycerol), and more recently, have been explored as possible agents to correct protein 
misfolding in cells and rescue the protein function. Some small chemical chaperones work as 
osmoylates, which are compounds affecting osmosis in solution. These compounds increase the 
hydration of the proteins. In turn, there will be free-energy differences between a partially folded 
protein and its native structure. Even though the underlying specific mechanism of the function 
of small chemical chaperones is not clearly understood, these non-specific and/or indirect 
functions do change protein folding and activity. Another group of chaperones are known as 
pharmacological chaperones. These typically are designed or found to bind to a structural motif 
that helps stabilize the folded protein and increase productive folding. A number of medications 
are now on the market based on this mechanism of action. Table 5 shows different diseases and 
the rescue of each condition with different chemical and/or pharmacological chaperones 
(Leandro and Gomes, 2008). Identifying novel compounds that might ultimately make successful 
drugs is a laborious and time-consuming process. Ideally, a high-throughput assay is available to 
monitor an effect on a specific target protein molecule or molecular phenotype would be 
valuable.  
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Table 5. Human proteins involved in misfolded disorders rescued by chemical and pharmacological 
chaperones  
Disease Protein involved Functional 
Localization 
Mechanism of 
Pathogenesis 
Chemical / 
Pharmacological 
chaperone 
Gaucher GC Lysosome Mistrafficking Deoxynojirimycin 
derivatives 
Fabry GLA Lysosome Mistrafficking Galatose, 1-deoxy-
galactonojirimycin 
Pompe GAA Lysosome Mistrafficking Deoxynojirimycine 
derivatives 
Tay-Sachs HEXA Lysosome Mistrafficking PYR; NGT 
Familial 
hypercholesterolemia 
LDL receptor Membrane Mistrafficking 4-PB 
Cystic fibrosis CFTR Membrane Mistrafficking Glycerol, DMSO, 
TMAO, 4-PB, TS3, 
VRT325; corr-2b; corr-
4a 
Nephrogenic diabetes 
insipidus X-linked 
V2R Membrane Mistrafficking SR121463B 
Nephrogenic diabetes 
insipidus type II 
AQP2 Membrane Mistrafficking Glycerol; TMAO; 
DMSO 
α1-antitripsin deficiency 1-AT Extracellular Mistrafficking Glycerol, 4-PB 
Retinitis pigmentosa CA IV Membrane Mistrafficking Acetazolamide; 
ethoxzolamide (enzyme 
inhibitors) 
Primary carnitine 
deficiency 
OCTN2 Membrane Mistrafficking 4-PB, quinidine, 
verapamil 
Albinism Tyrosinase Membrane Mistrafficking DOPA, Tyr 
Huntington Huntingtin Cytoplasm Aggregation Trehalose 
Hypogonadotroic 
hypogonadism 
GnRH receptor Membrane Mistrafficking Indol and Quinolone 
derivatives 
Machado-Joseph Ataxin-3 Nucleous/ 
cytoplasm 
Aggregation Glycerol, TMAO, 
DMSO 
Parkinson α-synuclein Cytoplasm Misfolding/ TMAO 
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aggregation 
Creutzfeldt-Jakob Prion Several cellular 
locali 
Aggregation Acridine-based 
analogue 
Alzheimer β-amyloid  Misfolding/ 
aggregation 
TMAO, glycerol 
Homocystinuria CBS Cytoplasm Misfolding TMAO, glycerol, 
sorbitol, L-proline; 
DMSO 
Phenylketonuria PAH Cytoplasm Misfolding Glycerol, BH4 
Maple syrup urine 
disease 
BCKD Mitochondria Misfolding TMAO 
Cancer P53 Nucleus Misfolding Glycerol, TMAO, D2O, 
CP249175, CP31398 
 
In recent study, Zhang et al. found that small molecule compounds can recover the 
PEX1-Gly843Asp proteins causing Zellweger spectrum disorder (ZSD). ZSD is a disorder in 
peroxisome biogenesis leading to the failure to assemble normal peroxisomes. It is genetically 
heterogeneous and is caused by mutation in one of nearly 20 genes. No effective therapy is 
available. PEX1-Gly843Asp can cause the misfolding of the PEX1 protein and lower the 
stability of the protein and degrade the protein. In patients’ fibroblasts having homozygous 
PEX1-Gly843Asp, only 5-15% of the PEX1 proteins were present compared to the wild type. 
The authors treated small molecule compounds for 48 hours and found the recovery of the 
proteins by confirming the recovery of the peroxisome structure using immunostaining (Zhang et 
al., 2010).  All these studies related to protein misfolding disorder using small chemical 
compounds as therapy support that small chemical chaperones can stabilize the K304E MCAD 
protein.  
 
Table 5 Continued 
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1.5.2 Small recovery of the MCAD activity is sufficient for MCADD therapy 
To investigate effective therapeutic approaches for MCADD, it is important to know the 
level of MCAD activity necessary to prevent the development of symptoms. In a recent study, 
Smith et. al. reported that minimal residual enzyme activity is sufficient to prevent MCADD 
(Smith et al., 2010). Therefore, potential MCADD therapies need not reproduce wild type 
MCAD activity levels. Rather even small increases in deficient patients will likely be sufficient 
to prevent the manifestations of MCADD.  
1.5.3 Small chemical chaperones therapy for MCADD 
Previously, many studies have shown that co-expression of the bacterial chaperonin 
GroEL/ES significantly stabilize the K304E MCAD protein (Bross et al., 1993). Also in 
eukaryotic system, down regulation of molecular chaperone, Hsp60, by RNAi impairs folding of 
wild type and mutant (K304E and R28C) MCAD proteins (Corydon et al., 2005). These support 
that molecular chaperones help the proper folding of the MCAD protein and by using small 
chemical chaperones we can rescue the MCAD protein folding and activity.  
1.5.4 Metabolism of Sodium Phenylbutyrate  
4-phenylbutyrate (PBA) is an aromatic fatty acid that composed of an aromatic ring with 
a butyric acid side chain (structure in table 7). It was originally used clinically as an ammonia 
conjugation agent, but has also been investigated as an inhibitor of the histone deacetylase 
HDACI, and as a non-specific chemical chaperone (Iannitti and Palmieri, 2011). In vivo, PBA 
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has been proposed to be activated to its CoA intermediate, then undergoes one round of 
mitochondrial fatty acid oxidation to its active form phenylacety-CoA (PAA). PAA can then be 
conjugated with one molecule of glutamine to form phenacetylglutamine (PGG), which can be 
excreted through urine. Thus, PBA provides an alternative source of ammonia excretion through 
PGG for patients with genetic defects of the urea cycle. PBA has also been shown to act as a 
histone deacetylase inhibitor (HDACI). Histone deacetylation can repress the transcriptional 
activation of genes and lead to gene silencing. Gene expression is a key process for cancer due to 
its function in cell growth and differentiations, and PBA has been proposed as a therapeutic 
option to control important cellular functions, including cell cycle arrest, induction of apoptosis, 
and activation of tumor suppressor genes, etc. Lastly, PBA has been studied as a chemical 
chaperone in protein misfolding disorders including cystic fibrosis, ischemia, Huntington 
disease, etc. (Iannitti and Palmieri, 2011). 
1.5.5 High-throughput screening (HTS) as a tool for investigating possible drug for 
MCADD 
HTS method is a well-established screening tool for drug discovery. It was first 
introduced in the mid-1990s to identify drugs for the treatment of human diseases (Mayr and 
Bojanic, 2009). HTS uses miniaturized assay systems, automation of the procedures, and large-
scale data analysis. Therefore, by using this method, the overall cost of the assays and time can 
be reduced significantly. This method has been used generally for investigating small-molecule 
lead compounds (Zhu and Cuozzo, 2009). Since small chemical libraries containing FDA 
approved drugs are commercially available, the development of HTS method for MCADD will 
be useful to save time and cost for MCADD drug discovery. Changes in either MCAD protein 
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expression or MCAD activity in the presence of drug can be measured to find the positive hits 
from these libraries. Miniaturization and optimization of the detection methods will be the first 
step for HTS in MCADD drug discovery. 
1.6 HYPOTHESES AND SPECIFIC AIMS OF THIS STUDY 
The overall hypothesis of this study is that even a small increase in MCAD activity will 
prevent clinical manifestations, and that protein stabilizing agents can increase MCAD enzyme 
activity in vivo and in vitro. My project has two main specific aims. Specific aim 1 is to study the 
effect of small chemical chaperones such as dimethylsulfoxide (DMSO), glycerol, 
trimethylamine N-oxide (TMAO), betaine, and L-proline on K304E mutant protein folding and 
activity. I hypothesize that incubation of these agents with MCAD deficient lymphoblasts will 
improve folding of the K304E MCAD protein and partially restore enzyme activity. Specific aim 
2 is to identify specific drug-targeting sites on the K304E MCAD protein in silico, as targets for 
therapeutic intervention. I hypothesize that synthetic peptides modeled on the K304E MCAD 
protein structure will promote stable folding of K304E MCAD protein and thus serve as a new 
class of molecules for chaperone therapy.  
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2.0  MATERIALS AND METHODS 
2.1 CELL CULTURE 
The cell lines used in this study and their sources are summarized in table 6. 
 
Table 6. Summary of cell types and source 
Cell name  Cell Type Source 
FB 554 Wild type human diploid fibroblasts Vockley lab  
GM13275 MCAD (K304E) patient diploid fibroblasts NIGMS Human Mutant Cell Repository, 
Coriell Institute, Camden NJ 
GM07844 MCAD (K304E) patient diploid fibroblasts NIGMS Human Mutant Cell Repository, 
Coriell Institute, Camden NJ 
TL 596 Wild type lymphoblasts (EBV transformed) Vockley lab  
TL 598 Wild type lymphoblasts (EBV transformed) Vockley lab  
TL 671 MCAD (K304E) patient lymphoblasts (EBV 
transformed) 
NIGMS Human Mutant Cell Repository, 
Coriell Institute, Camden NJ 
TL 672 MCAD (K304E) patient lymphoblasts (EBV 
transformed) 
NIGMS Human Mutant Cell Repository, 
Coriell Institute, Camden NJ 
pcDNA HEK 293 T-REX Flp-In pcDNA; a 
transformed epithelial cell line with an empty 
(control) pcDNA vector integrated 
Dr. Thomas Corydon, Aarhus University, 
Aarhus, Denmark 
MCAD HEK 293 T-REX Flp-In MCAD (wild type); 
a transformed epithelial cell line with an 
integrated pcDNA vector containing a wild 
type MCAD cDNA insert 
Dr. Thomas Corydon, Aarhus University, 
Aarhus, Denmark 
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K304E HEK 293 T-REX Flp-In MCAD (K304E); a 
transformed epithelial cell line with an 
integrated pcDNA vector containing a 
MCAD K304E cDNA insert 
Dr. Thomas Corydon, Aarhus University, 
Aarhus, Denmark 
R28C HEK 293 T-REX Flp-In MCAD (R28C); a 
transformed epithelial cell line with an 
integrated pcDNA vector containing a  
MCAD  R28C cDNA insert 
Dr. Thomas Corydon, Aarhus University, 
Aarhus, Denmark 
 
2.1.1 Human diploid fibroblasts 
Wild type and MCADD patients’ fibroblasts were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 1% L-glutamine, 1% penicillin streptomycin and 15% fetal 
bovine serum (FBS) at 37°C, 5% CO2, and humid incubator. 
2.1.2 HEK 293 T-REX Flp-In inducible cell line 
All HEK 293 T-REX Flp-In inducible cell lines were cultured in Dulbecco’s Modified 
Eagle Medium (DMEM) supplemented with 1% L-glutamine, 1% penicillin streptomycin and 
15% fetal bovine serum (FBS) at 37°C, 5% CO2, with humidity. 100μg/ml of hygromycin and 
15μg/ml blasticidin were also added to ensure continued integration of the vectors. 1μg/ml of 
tetracyclin was added to induce the vector insert.   
Table 6 Continued 
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2.1.3 Human lymphoblasts 
Both wild type and MCADD patients’ lymphoblasts were cultured in Roswell Park 
Memorial Institute (RPMI) medium supplemented with 1% L-glutamine, 1% penicillin 
streptomycin and 15% fetal bovine serum (FBS) at 37°C, 5% CO2, with humidity. 
2.2 HIGH-THROUGHPUT IMMUNOASSAY FOR MCAD STABILITY 
To facilitate screening of a chemical library for compounds with chaperonin activity for 
mutant MCAD, a high-throughput immunoassay was developed. Wild type and MCADD mutant 
human diploid fibroblasts were seeded at 3,000 cells per well in collagen coated 384-well black-
walled clear-bottom plates and cultured overnight at 37°C, 5% CO2, with humidity. The next 
day, cells were washed once with Dulbecco’s phosphate buffered saline (PBS) without Ca2+ or 
Mg2+ and fixed with 3.7% formaldehyde containing Hoechest dye for 10 minutes at room 
temperature. Cells were permeabilized with 0.5% Triton X-100 in PBS for 90 seconds at room 
temperature then washed with PBS. Either polyclonal or monoclonal primary MCAD antibody 
(1:62.5 dilution in TBST) was incubated for 1 hour at room temperature. Then, cells were 
washed with PBS and secondary Alexa Fluor® AF488 anti-rabbit antibody (1:500 dilution in 
TBST) was added and incubated for 1 hour at room temperature. After secondary antibody 
incubation, cells were washed with PBS and the cell plates were sealed and imaged by the 
ArrayScan VTI imaging platform. 
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2.3 SMALL CHEMICAL CHAPERONES   
DMSO, TMAO, L-proline, betaine, glycerol, and 4-phenylbutrate were purchased from 
Sigma (St. Louis, MO). DMSO, glycerol, TMAO, and 4-phenylbutyrate were dissolved in tissue 
culture media and filter sterilized. L-proline and betaine were dissolved in distilled water and 
filter sterilized. Table 7 shows the structure of each chemical (http://pubchem.ncbi.nlm.nih.gov/).  
 
Table 7. Structures of small chemical chaperone 
Name Molecular 
formula 
Molecular weight Structure 
DMSO C2H6OS 78.13344 
 
TMAO C3H9NO 75.10966 
 
Betaine C5H11NO2 117.14634 
 
Glycerol C3H8O3   92.09382 
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L-proline C5H9NO2    115.13046   
 
4-phenylbutrate C10H12O2   164.20108   
 
2.4 PROTEIN QUANTIFICATION  
Proteins from cell free extracts or bacterially purified proteins were quantified by DC 
Protein Assay Kit from BioRad (Hercules, CA). 
2.5 PROTEIN PURIFICATION  
2.5.1 MCAD purification 
Expression of recombinant human MCAD protein expression plasmids was as described 
(Matsubara et al., 1989). Briefly, pKe-MCAD and pKe-MCAD K304E, were co-transformed with 
pGroEL/GroES (encoding the bacterial chaperonin GroEL and GroES genes) in E. coli JM105 
Table 7 Continued 
 36 
cells (Amersham Biosciences Crop; Piscataway, NJ). Cells were grown overnight with 
antibodies, ampicillin (100μg/ml) and chloramphenicol (50μg/ml) at 37°C with shaking, and the 
vectors were induced by the addition of 0.5mM isopropyl β-D-1-thiogalactopyranoside (IPTG) 
for three hours at 30°C. Cells were harvested by centrifugation, lysed by sonication on ice and 
subjected to centrifugation at 250,000 x g for 30 minutes. Cell free extracts were fractionated 
sequentially with 30% and 50% ammonium sulfate.  The final ammonium sulfate pellet was 
dissolved in 50mM potassium phosphate buffer (KP, pH 8.0) and 25μM FAD dialyzed for 4 
hours in the same buffer, then subjected to centrifugation for 20 minutes at 19,000 rpm at 4°C. 
Supernatant was loaded onto a DEAE (diethylaminoethyl) SepharoseTM fast flow (GE Health 
care Life sciences; Piscataway, NJ) column by using an ÄKTA UPC-900 pump FPLC system 
(Amersham Biosciences Corp; Piscataway, NJ) and eluted with a gradient of 50mM KP to 400 
mM KP, pH8.0. Fractions were tested for the presence of MCAD protein by SDS-PAGE and 
Coomassie blue staining. Those containing the highest amount of protein were pooled, buffer 
exchanged in a Centriprep 30K (Merk Millipore LtD; Darmstadt, Germany) to a 10 mM KP (pH 
8.0) loaded onto a CHTTM ceramic hydroxyapatite type I (BioRad; Hercules, CA) column, and 
eluted with a linear gradient to 300 mM KP, pH 8.0. Peak fractions containing MCAD protein 
were identified by spectrophotometer at 447nm.  
2.5.2 ETF purification 
ETF isolation method was performed as described (Vockley et al., 2000). Briefly, fresh 
pig liver was cut into small pieces and washed with PBS to remove the blood. The tissue was 
homogenized by blending in 50 mM KPO4 (pH 8.0), 1 mM EDTA, 2.5% glycerol and 250 mM 
sucrose, filtered through cheese clothes. Cellular debris was removed by low speed 
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centrifugation, 2,500 rpm in a Beckman J6-HC, followed by a higher speed centrifugation, 9,000 
rpm in Sorval RC 5B Plus, to pellet mitochondria. The pellet was washed at least 3 times in 
homogenization buffer. The final pellet was stored at -80°C. For ETF purification, pellets 
weighing 400-500 mg were mixed 0.3:1 (volume: weight) with 10 mM EDTA, 3 mM K2HPO4 
(pH8.0), 0.12 mM FAD, and 0.541 mM AMP, sonicated on ice, then subjected to centrifugation 
at 250,000 X g. The supernatant was fractionated by ammonium sulfate (40% then 60%). The 60% 
fraction pellet was dissolved in sonication buffer and dialyzed extensively in three changes of 15 
mM K2HPO4 (unbuffered) and 5% glycerol overnight, and the dialysate was loaded onto a 
DEAE-sepharose column (GE Health care Life sciences; Piscataway, NJ) and eluted with 15 mM 
K2HPO4 (unbuffered) and 5% glycerol. Fractions containing significant fluorescence under UV 
light were pooled and applied to a carboxymethyl (CM) Sepharose column (GE Health care Life 
sciences; Piscataway, NJ) and eluted with a gradient of 10 mM Tris, pH 8.5 to 10 mM Tris, 100  
mM NaCl, pH8.5. Fractions with an A270/A436 ratio below 8 were pooled and used for regular test 
assays, or further applied to a ceramic hydroxyapatite column (BioRad, Hercules, CA). Fractions 
with an A270/A436 ratio below 6.5 were pooled for kinetic studies.  
2.6 SDS-PAGE 
For visualization of fractionated proteins samples, aliquots were separated on 4-12 %T 
Tris gels or 16.5 %T Tricine gels and stained with either Coomassie blue (0.025% Coomassie 
blue R-250 in 40% methanol, and 7% acetic acid) or a with ProteoSilverTM Plus Silver Stain Kit 
from Sigma (St. Louis, MO).  
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2.7 ETF FLUORESENCE REDUCTION ASSAY 
Anaerobic ETF fluorescence reduction assay using a rubber sealed cuvette with sample 
deaerated with argon and vacuum was performed using a Jasco FP-6300 fluorescence 
spectrofluorometer (Easton, MD) to measure the MCAD and VLCAD activity as described 
(Frerman and Goodman, 1985). Samples were mixed with reaction buffer containing 50 mM 
Tris, pH8.0, 0.5% glucose and 30µM octanoyl-CoA as a substrate for MCAD activity. 
Palmitoyl-CoA was used in the same concentration as control in cellular extracts. Octanoyl-CoA 
and palmitoyl-CoA were purchased from Sigma (St. Louis, MO). Background fluorescence was 
measured in the absence of ETF. Then, ETF was added to a 2μM final concentration and 
baseline fluorescence of the reaction mixture was determined. The reduction in fluorescence over 
30 sec was monitored and the rate was calculated. One mU of activity is defined as the amount 
of enzyme necessary to completely reduce on μ mole of ETF in 1 minute (Frerman and 
Goodman, 1985). To test for thermal stability, MCAD protein at 130nM and the MCAD:ETF at 
10 mM of docking site peptide, wild type sequence or mutant,  were incubated on ice for 10 
minutes,  10μL final volume in  50 mM Tris (pH 8.0) buffer. Each sample was incubated at 
temperature ranging from 30ºC to 62.5ºC with increments of 2.5ºC for 5 minutes, then assayed 
for residual MCAD activity.  
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2.8 SAMPLE PREPARATION FOR ETF ASSAY 
2.8.1 Treatment of cells with chemical chaperones 
Wild type and patient lymphoblasts were incubated for 48 hours in 0.5% glycerol, 3% 
DMSO, 100 mM betaine, 200mM TMAO, or 300 mM L-proline were treated with both wild type 
and patients’, having homozygous K304E mutant lymphoblasts. The lymphoblasts were 
harvested by centrifugation, lysed in a water bath sonicator, Misonix S-4000 (Misonix, 
Farmingdale, NY). The protein concentration of the supernatant was measured using the DC the 
protein assay kit from BioRad (Hercules, CA) and ACAD activity was measured with the ETF 
reduction assay. Wild type and K304E MCAD mutant lymphoblasts and diploid fibroblasts were 
incubated with sodium phenylbutyrate (0.5 mM or 1 mM) and cultures for 48 hours at 37ºC. 
Cells were harvested by centrifugation and assayed for protein and ACAD activity as above.  
2.8.2 ETF and peptide experiment 
130 nM of MCAD protein and 10 mM of selected peptide targeting ETF docking were 
incubated on ice for 10 minutes. Then whole reaction mixture was used for ETF assay.  
2.8.3 ETF assay sample preparation for peptide thermal stability experiment 
The sample preparation was done like previously in peptide experiment. 130nM of MCAD 
protein and 10 mM of selected peptide were incubated on ice for 10 minutes. Then, each sample 
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was incubated at the assigned temperature for 5 minutes. Assigned temperatures ranged from 
30ºC to 62.5ºC with data acquired every 2.5°C. 
2.9 DCIP ASSAY 
2,6 Dichlorophenol-Indophenol (DCIP) dye reduction assay was performed to investigate 
the MCAD activity independent of ETF interaction. Phenazine methosulfate (PMS) was used as 
an intermediate electron acceptor with DCIP was used as the final electron acceptor and reaction 
indicator. The reaction mixture contained 100mM potassium phosphate (pH 8.0), 3mM PMS, 
100µM FAD, and 60µM substrate, and was started with octanoyl-CoA added to a final 
concentration of 50µM. The reduction of absorbance was measured at 600nm using a Jasco V-
650 spectrophotometer. MCAD activity was calculated as follows: Activity/ml = O.D.600 X 47.6 
X 1000/ volume of enzyme used. One mU of activity is defined as the amount necessary to 
completely reduce one µM of DCIP. 
2.10 QUANTITATIVE REVERSE TRANSCRIPTION PCR 
Total RNA was isolated from cells treated with chemical chaperones using the RNeasy 
Mini Kit (Qiagen). One microgram of RNA was reverse transcribed (SuperScript III, Invitrogen) 
with random hexamer or oligo (dT) primers in a 20μl reaction. ACADM sequences were 
quantitated in triplicate by qPCR in an Applied Biosystems 7300 Real Time PCR system with 
SYBR green (Power SYBR® Green PCR Master Mix, Applied Biosystems) as the fluorescent 
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label, GAPDH primers were used as for normalization. Threshold cycle (CT) was reported. Table 
8 shows the primers for qPCR.  
 
Table 8. Primers 
Primer name  Nucleotide Sequence 
Human GAPDH 5’ 5' ATG GAA ATC CCA TCA CCA TCT T 3' 
Human GAPDH 3’ 5' CGC CCC ACT TGA TTT TGG 3' 
hMCAD 164-188 5’ 5’ TTG CCA GAG AGG AAA TCA TCC CAG T 3’ 
hMCAD 478-452 3’ 5’ CAC AAT AAG CAC ACA TCA ATG GCT CG 3’ 
2.11 STRUCTURAL ANALYSIS OF MCAD PROTEIN 
To analyze the MCAD K304E structure, published crystal structures of MCAD from 
different species were compared. Table 9 shows the sources of crystal structure of MCADs.  
 
Table 9. Description of analyzed crystal structure of MCAD protein 
PDB ID Description Reference 
3MDE The pig MCAD structure with octanoyl-CoA (Kim et al., 1993) 
3MDD The pig MCAD structure (Kim et al., 1993) 
2A1T The human MCAD:ETF βE165A complex (Toogood et al., 2005) 
1UKW The crystal structure of MCAD from Thermus 
thermophilus HB8 
Atomic coordinates 
only deposited under 
the code 1UKW 
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2.12 GENERATION OF ETF DOCKING SITE BINDING SYNTHETIC 
PEPTIDES 
A crystal structure of an MCAD:ETF complex has been reported (Toogood et al., 2004).  
Based on this model, 12-mer peptides were designed for enhanced binding to the MCAD ETF-
docking site, ETF amino acid residues Arg191 to Lys202, using InsightII (Accelrys) Molecular 
Modeling software package. Figure 13 shows a ribbon representation of MCAD monomer and 
the ETF docking peptide. The various peptides were synthesized at the University of Pittsburgh 
Genomics and Proteomics Core Laboratories. Table 10 shows the amino acid sequence of 
various synthetic peptides. 
                
Figure 13. Ribbon representation of the MCAD ETF docking site (gray ribbons) and the ETF 
docking peptide 
ETF βR191-βK202 (blue ribbon). (The rest of the MCAD tetramer and ETF dimer are hidden) 
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 Table 10. Amino acid sequences of the synthetic ETF docking site peptide sequences 
YAT 191 (Wild type) RYATLPNIMKAK 
YAT 2    YATLPNIMKAK 
YAT 193 YAT193* 
YAN   YANLPNIMKAK 
YANF    YANLPNIFKAK 
YRQF    YRQLPNIFSN 
YRQR    YRQLPNIRSN 
YAT 194 RYANMPNIFKAK 
YAT 195 RYATLPNIFKAK 
YAT 196 RYANLPNIFKAK 
*Sequence not revealed for patent rights 
2.13 CIRCULAR DICHROISM (CD) 
Purified recombinant wild type or K304E MCAD protein at 5μM concentration was 
mixed with an MCAD:ETF docking peptides to give 1mM final concentration in 25mM KP 
buffer, pH8.0. CD and US-visible spectral changes were measured with a Jasco J-810 
Spectropolarimeter at 445nm with 1ºC increase from 33ºC to 73ºC. At each temperature, the 
machine equilibrated for 1 minute, then the CD spectrum was acquired as the difference in 
fluorescence intensities for left and right circularly polarized excitation.  
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2.14 LIMITED PROTEOLYSIS 
Ten micrograms of purified recombinant wild type and K304E mutant MCAD protein 
were co-incubated with an MCAD:ETF docking peptide with or without Staphylococcus aureus 
V8 protease in 50mM NH4 bicarbonate buffer, pH8.0, a buffer favoring Glu-C hydrolysis. The 
reaction was initiated by adding the protease at a MCAD:protease ratio of 20:1 (w/w)  and then 
incubating at 37°C. Samples were collected at 0, 2.5, 5, 7.5, 10, 15, and 30 minutes. A no 
protease control was incubated for 30 minutes in the same buffer. Reactions were stopped by 
adding Laemmli SDS-PAGE sample buffer and boiling the collected samples for 5 minutes. 
Peptide patterns were visualized by separation on 16.5% Tris-Tricine gels, followed by silver 
staining with ProteoSilverTM Plus Silver Stain Kit from Sigma (St. Louis, MO). Peptide bands 
were identified by excising them from the gel and subjected to mass spectrometry by the 
University of Pittsburgh Genomic and Proteomic Core Laboratory. To test the protease sensitive 
enzyme activity, 35nM of MCAD protein and 3mM of a peptide targeting MCAD:ETF docking 
were incubated on ice for 30 minutes,  6.7 μL total volume in 50mM NH4 bicarbonate buffer, 
pH8.0, with or without Staphylococcus aureus V8 protease at 750 units. Then entire reaction 
mixture was used as sample for the ETF reduction assay.  
2.15 DENSITOMETRIC ANALYSIS OF PROTEIN BANDS 
Determination of the rates of generation of the MCAD proteolytic peptides after SDS 
PAGE with silver or Coomassie Blue staining, and western blot bands were carried out using 
Alpha Imager 2200, and AlphaEaseFCTM software following scanning with a computer driven 
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Epson, Inc scanner. Distinct protein bands were quantitated and normalized by its background. 
Calculated protein density numbers were then compared to each other.  
2.16 MS/MS ANALYSIS 
After limited proteolysis, Coomassie stained gels were washed with water and band of 
interest was excised and analyzed by University of Pittsburgh Genomics and Proteomics Core 
Laboratories. 
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3.0  RESULTS 
3.1 DEVELOPMENT OF A HIGH-THROUGHPUT SCREENING ASSAY 
FOR MCADD 
Screening chemical libraries for compounds that are clinically active in a specific 
disorder is laborious and time consuming. Most drug discovery programs screen tens or hundreds 
of thousands of molecules to identify second tier candidates. There are two options to expedite 
this process. First, the development of a high-throughput screening assay system allows large 
numbers of compounds to be tested quickly, reserving more specific assays for follow up studies. 
Alternatively, a more targeted approach in selecting candidate molecules based on a prior 
knowledge of the system in combination with in silico design might allow testing of fewer 
candidate compounds. To explore the first possibility, a high-throughput screening assay method 
for MCADD based on immunostaining of MCAD protein in patient fibroblasts was tested. Wild 
type or one of the two different MCADD patient fibroblasts were seeded into 384 well plates and 
MCAD antigen was visualized in an automated ArrayScan VTI imaging platform after reacting 
with an MCAD specific monoclonal or polyclonal antibody (Figure 14 and 15).  Unfortunately, 
all three cell lines stained nearly equally, and thus could not be differentiated under these 
conditions. Of note, publications to date have differed on the presence or absence of antigen in 
patient cells.  
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 (a)                                                         (b)                                                        (c) 
 
  (d)                                                    (e)                                                    (f) 
  
 
 
 
Figure 14. Immunofluorescent staining of MCAD staining in fibroblasts with polyclonal MCAD 
antibody 
Human diploid fibroblasts from control and two different patients were seeded at 3,000 cells per well in collagen 
coated 384 well plates and cultured overnight at 37°C. The next day, the cells were permeabilized and incubated 
with a polyclonal MCAD antibody. The plates were sealed and imaged by the ArrayScan VTI imaging platform. 
Blue indicates the nuclear staining and green indicates MCAD protein. (a,d: Wild type fibroblasts, b,e: GM13275, 
c.f: GM07855) 
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  (a)                                                    (b)                                                    (c) 
 
  
(d)                                                    (e)                                                    (f) 
 
 
 
Figure 15. Immunofluorescent staining of MCAD staining in fibroblasts with monoclonal MCAD 
antibody 
Human diploid fibroblasts from control and two different patients were seeded at 3,000 cells per well in collagen 
coated 384 well plates and cultured overnight at 37°C. The next day, the cells were permeabilized and incubated 
with a monoclonal MCAD antibody. The plates were sealed and imaged by the ArrayScan VTI imaging platform. 
Blue indicates the nuclear staining and green indicates MCAD protein. (a,d: Wild type fibroblasts, b,e: GM13275, 
c.f: GM07855) 
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3.2 SMALL CHEMICAL CHAPERONES STABILIZE MCAD IN MUTANT 
LYMPHOBLASTS 
3.2.1 Basal MCAD enzyme activity and ACADM gene expression in lymphoblasts 
As proof of principle before starting large-scale chemical screening studies, several small 
chemicals with known protein stabilization properties were tested for their ability to rescue 
activity in lymphoblasts homozygous for the K304E MCAD mutation. Basal MCAD enzyme 
activity in these cells was measured first (Figure 16). Lymphoblasts from a control (596) and two 
different MCAD patients (671 and 672), were cultured at 37°C and 30°C respectively, and 
enzyme activity was tested. MCAD activity was almost zero in patient lymphoblasts but was 
easily detectable in control cells at both temperatures.  
 
 
Figure 16. Basal MCAD enzyme activity in lymphoblasts 
Both wild type (596) and MCADD patients’ (671 and 672) lymphoblasts were grown at different temperature, 37°C 
and 30°C. Then cells were lysed and cell free extracts were assayed for MCAD activity using ETF fluorescence 
reduction assay. Assays were duplicated and average values were plotted.  
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 The reduction in MCAD activity in K304E patient lymphoblasts was not due to changes in gene 
expression, which was similar in all cell lines (Figure 17). 
                              
Figure 17. Quantification of the ACADM expression in lymphoblasts by qRT-PCR 
Wild type (596) and MCADD patients’ (671 and 672) lymphoblasts were cultured and the RNA from these cells 
was extracted and qRT-PCR was performed. Error bars represent standard deviation. 
 
3.2.2 Small chemical chaperones increase the activity of K304E mutant MCAD in 
patients’ lymphoblasts 
To investigate the effect on enzyme stability, lymphoblasts cultures were incubated with 
a variety of small chemicals with protein stabilization properties, DMSO, glycerol, betaine, 
TMAO, and L-proline, and tested for MCAD activity. Patient cells showed a significant increase 
in MCAD activity with glycerol and TMAO treatment (Figure 18).  
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Figure 18. The MCAD activity changes in the presence of small chemical chaperones 
Both wild type (596) and MCADD patients’ (671 and 672) lymphoblasts were cultured for two days at 37°C with 
different small chemical chaperones (3% DMSO, 0.5% glycerol, 100mM betaine, 200mM TMAO, or 300mM L-
proline). Then cells were harvested and lysed. Cell free extracts were assayed for MCAD activity using ETF 
fluorescence reduction assay. Assays were duplicated and average values were plotted. 
 
To test whether these small chemical chaperones can influence the activity of other 
ACADs, VLCAD activity was measured. While glycerol and TMAO increased the K304E 
MCAD activity, there was no increase in VLCAD activity with the treatment of either glycerol 
or TMAO (Figure 19). The VLCAD activity in both wild type and K304E MCAD expressing 
lymphoblasts decreased in the presence of glycerol and TMAO. This indicates that the small 
chemical chaperones affect the K304E mutant MCAD activity but doesn’t provide similar 
increasing effect in VLCAD activity. 
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Figure 19. Relative VLCAD enzyme activity changes in lymphoblasts treated with glycerol or TMAO 
Both wild type (596) and MCADD patients’ (671 and 672) lymphoblasts were cultured for 2 days at 37°C with 0.5% 
glycerol or 200mM TMAO, and then cells were harvested and lysed. Cell free extracts were assayed for VLCAD 
activity using ETF fluorescence reduction assay. Assays were duplicated and average values were plotted. 
 
To determine if these effects were due to transcriptional overexpression, qPCR was used 
to examine the level of MCAD mRNA sequence in cells under each condition (Figure 20).  
While the patient cell line 672 had a slightly higher level of MCAD message compared to 671, 
treatment with the small molecule chaperones did not affect the level in either cell line. The 
treatment of glycerol and TMAO reduced VLCAD enzyme activity both in wild type and MCAD 
deficient lymphoblasts.  The mechanism is unclear but this can be due to the toxicity of the 
glycerol and TMAO.   
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Figure 20. The ACADM, MCAD coding gene, expression in lymphoblasts with the treatment of 
different chemical chaperones by qRT-PCR 
Both wild type (596) and MCADD (671 and 672) lymphoblasts were cultured with different small chemical 
chaperones for two days. Then, the RNA from these cells were extracted and qRT-PCR was performed. Error bars 
represent standard deviation. 
3.3 PHENYLBUTYRATE AS A POTENTIAL TREATMENT FOR MCADD. 
As demonstrated in Chapter 5 of this thesis, phenylbutyryl-CoA is a substrate for MCAD 
(Kormanik et al., 2012).  Phenylbutyrate (PBA) is an FDA approved medication used to treat 
inborn errors or the urea cycle. Substrate analogues are among the most potent small molecules 
enhancer of protein folding, and so it has been hypothesized that phenylbutyryl-CoA could work 
as a chaperone for the K304E MCAD protein. To examine this possibility, phenylbutyryl-CoA or 
octanoyl-CoA was incubated with purified recombinant K304E MCAD protein without a 
secondary electron acceptor at different temperatures for 5 minutes and residual MCAD activity 
was measured. Under these conditions, substrate remains bound with enzyme as a stable charge-
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complex intermediate. Phenylbutyryl-CoA proved to be as nearly as effective at stabilizing 
K304E MCAD protein as octanoyl-CoA, the optimum substrate for MCAD (Figure 21).  
 
 
Figure 21. Thermal stability of the K304E mutant MCAD protein with and without added 
phenylbutyryl- CoA or octanoyl-CoA 
The recombinant K304E MCAD protein was incubated at different temperatures (30°C to 62.5°C) with 2.5°C 
increment for 5 minutes in the presence or absence of phenylbutyryl-CoA or octanoyl-CoA. Assays were duplicated 
and average values were plotted. 
 
To further test the effect of PBA on K304E MCAD activity, lymphoblasts were cultured 
with PBA and the MCAD activity was measured (Figure 22 and 23). Although the basal MCAD 
activity was difficult to measure in MCAD deficient cells (671 and 672), there was consistent 
pattern of increase of MCAD activity with phenylbutyrate in MCAD deficient patients’ 
lymphoblasts.  
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 Figure 22. The effect of phenylbutyric acid on MCAD activity in wild type (596 and 598) 
lymphoblasts 
Both wild type (596) lymphoblasts were cultured for two days at 37°C with 4mM and 10mM of phenylbutyrate. 
Then cells were harvested and lysed. Cell free extracts were assayed for MCAD activity using ETF fluorescence 
reduction assay. Assays were duplicated and average values were plotted. 
 
 
 
Figure 23. The effect of phenylbutyric acid on MCAD activity in MCAD deficient (671 and 672) 
lymphoblasts 
MCAD deficient (671 and 672) lymphoblasts were cultured for two days at 37°C with 4mM and 10mM of 
phenylbutyrate. Then cells were harvested and lysed. Cell free extracts were assayed for MCAD activity using ETF 
fluorescence reduction assay. Assays were duplicated and average values were plotted. 
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 Because the staining levels of MCAD activity in fibroblasts and lymphoblasts are low, it 
was difficult to quantitate changes in treated cells relative to untreated cells. To increase the 
MCAD signal mutant and wild type MCAD were overexpressed in HEK 293 cells using a T-
REX Flp-In inducible vector. In this system, the vector insert is induced using tetracycline. 
Treatment of cells expressing wild type and mutant MCADs with 0.5mM phenylbutyrate 
increased activity in cells expressing wild type enzyme significantly compared to untreated cells, 
without increasing the amount of MCAD protein (Figure 24 and 25). In contrast, phenylbutyrate 
increased MCAD activity and protein in cells expressing mutant MCAD.  
 
       
 
Figure 24. The effect of phenylbutyrate on MCAD activity in HEK 293 T-REX Flp-In inducible cell 
line 
HEK 293 T-REX Flp-In pcDNA, MCAD, and K304E expressing cell lines were cultured for two days at 37°C with 
0.5mM and 1mM of phenylbutyrate. Then cells were harvested and lysed. Cell free extracts were assayed for 
MCAD activity using ETF fluorescence reduction assay. Error bars represent standard deviation. 
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 The MCAD expression in different cell lines was detected by western blotting and 
relative protein density was measured using Alpha Imager 2200 (Figure 25). The expression of 
K304E MCAD protein was increased in the presence of 0.5mM phenylbutyrate treatment.  
 
 
                                               
Figure 25. Relative protein densitometry of the MCAD protein in HEK 293 T-REX Flp-In inducible cell line 
Anti-MCAD western blotting of phenylbutyrate treated HEK 293 T-REX Flp-In cell extracts. Twenty-five 
microgram total protein was loaded per lane.  
3.4 INVESTIGATION OF DRUG TARGET SITE OF MCADD 
The experiments with phenylbutyrate show the potential benefit of small chaperones as a 
therapy for MCAD deficient patients harboring at least one copy of the common mutation. 
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importance of identifying additional binding sites on the protein with pharmacophore 
characteristics favorable for binding highly specific potential drugs and stabilizing the mutant 
MCAD. To identify such possible drug targeting site for K304E MCAD protein, recombinant 
K304E MCAD purified to essential homogeneity was supplied to our collaborator Dr. Kevin 
Battaile for crystal growth and X-ray crystallography and the K304E MCAD crystal structure 
was determined at to 1.73 Å resolution 
3.4.1 Structural analysis of MCAD K304E protein 
The MCAD K304E protein crystal structure was resolved to 1.73 Å. This structure was 
compared to published crystal structures of MCAD from various sources, including pig (PDB: 
3MDE), (J-J Kim 1993), human MCAD complexed with ETF βE165A (PDB code: 2A1T), 
(Toogood et al., 2005), and bacteria (PDB: 1UKW). The crystal structure findings substantiated 
that the structure of the mutant MCAD enzyme was relatively unaltered and the atomic 
coordinates at such high resolution can be used in silico chemical library screening and for 
structure or fragment based drug design. 
The MCAD Tetramer Core: While in the wild type, K304 Nζ, located in Helix H, is 
shown consistently within a hydrogen bonding distance to the amide oxygen of Q342 (Helix I), 
in the MCAD K304E mutant the carboxylate at the 304 position induces the amide group to 
move away from its original position by 3.6 Å rotating the Q342 Cα-Cβ bond by ~97º degrees 
(Figure 26). This change in conformation positions the amide group oxygen closer by one Å to 
D346 carboxylate oxygen OD1 and within an interacting distance <3.0 Å. In addition to these 
structural perturbations, the methyl group of the thiomethyl moiety of M297, Helix H, seemed to 
also move away from facing the D346 residue to the opposite side of the methionine sulfur. 
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Other subtle structural perturbations that are secondary have also been observed in this region 
but cannot be confirmed to be directly or indirectly induced by the mutation at the 304 position. 
                       
Figure 26. Ribbon and stick representation of parts of the MCAD protein at its core 
The key amino acids at K304 and Q342 are shown in stick model. Original wild type residues carbons are shown in 
orange and the residues carbons in the mutant protein are shown in green.  
 
The MCAD Active Site: The most important changes in the active site are apparent when 
comparing the conformations of residues in the absence and presence of the octanoyl-CoA ligand 
and relate those observed conformations in the MCAD K304E mutant and the MCAD in the 
presence of ETF. Octanoyl-CoA binding induces displacement of a string of water molecules, 
802 to 805, occupying the active site at the octanoyl moiety binding site.  While the of E376 is 
positioned closer to the FAD isoalloxazine ring in the structure without the substrate in the pig 
MCAD as in the human MCAD K304E structure, it is observed to move away by 1.9 Å in the 
presence of the octanoyl moiety of the CoA ester and, interestingly, to the same position as 
observed in the MCAD:ETF ternary complex. This implies similar conformational changes are 
induced by the binding of substrates, either the acyl-CoA or ETF, to MCAD and is consistent 
with a hypothetical induced fit mechanism.  Another active site residue of interest is E99. In the 
MCAD K304E mutant, its γ-carboxylate is observed at a similar position to the one in the 
MCAD in the absence of either the octanoyl-CoA or ETF substrates. In the MCAD with 
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octanoyl-CoA bound, substrate binding induces a dramatic 4.1 Å movement away from its 
location to allow for the octanoyl binding.  
The ETF Docking Site: Residues at ETF docking site of the MCAD protein were 
carefully examined because of the potential of the site for drug development. Human MCAD 
complexed with ETF βE165A was compared to MCAD K304E mutant and pig MCAD with and 
without substrate. The ETF docking interface includes two major areas, the docking site pocket 
and the docking pocket surrounding surface. The docking site pocket is essentially all 
hydrophobic formed by residues that are part of helices, A, C, and D and the loop connecting 
helices C and D. Specifically, the F23, T26, A27, L59, G60, L61, L73, L75, and I83 residues line 
the inside of this pocket. Among these residues G60 is the only invariant residue in all ACADs, 
while others are either highly conserved, e.g. F23, L59, and L61, or conserved, e.g., L73, L75, 
I83. When comparing available, published MCAD crystal structures, these residues within the 
docking site pocket have similar conformations. There are some minor changes in the 
MCAD:ETF co-structure, where conformational changes induced by ETF binding include tilting 
of the phenyl moiety of F23 by almost 90 degrees to allow for the protrusion of the leucine β195 
residue into the docking site pocket. On the docking pocket surrounding surface there are other 
apparently important interactions including interactions of the ETF Yβ192 residue, which is 
invariant among all known ETF proteins, with residues on the MCAD including a hydrogen 
bond between the hydroxyl hydrogen and the carboxyl oxygen of glutamate 34, which is 2.6 Å 
away, and interactions of βY192 residue with L59 and R55 that are 2.9 Å and 3.1 Å away, 
respectively. Another residue is the ETF βA193 with it backbone oxygen at a 2.7 Å distance 
from MCAD T26 hydroxyl oxygen, which is not conserved in other ACAD proteins. Table 11 
summarizes the key contacts between ETF and MCAD proteins. 
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Table 11. ETF docking peptide key interacting atoms at the ETF:MCAD interface 
ETF Residue MCAD Residue* Distance (Å) 
Tyr β192:CD2 Leu59:CD2 3.8 
Tyr β192:CD1 Tys29:CD 4.0 
Tyr β192:CE1 Tys29:CD 3.6 
Tyr β192:CE1 Tys29:CG 3.2 
Tyr β192:CE1 Tys29:CB 3.5 
Tyr β192:CB Leu59: CD2 3.9 
Tyr β192:CE2 Arg55:NH2 3.1 
Tyr β192:CG Leu59:CD2 2.9 
Tyr β192:OH Glu34: OE1 2.6 
Ala β193:O Thr26:OG1 2.7 
Thr β194:OG1 Glu58:O 3.9 
Leu β195:CG Gly60:O 3.9 
Leu β195:CG LeuD59:O 3.8 
Ile β198:CG2 Glu22:OE1 3.5 
Ile β198:CD1 Glu22:O 3.6 
Ile β198:CD1 Thr26:OG1 4.0 
Ile β198:CD1 Glu22:CB 3.9 
Ile β198:CG2 Glu22:CB 3.7 
Ile β198:CG2 Gln19:CG 3.9 
Met β199:CA Gln19:NE2 3.6 
Lys β202:NZ Gln19:CG 3.6 
*Atoms’ designation as they appear in the PDB atomic coordinates file.  
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3.4.2 Synthetic ETF docking peptide analogs compete with ETF binding to wild type and 
K304E mutant MCAD  
If the synthetic ETF docking site peptides effectively interact with MCAD, then they 
should compete with native ETF for binding and reduce its ability to reoxidize the enzyme in the 
ETF-fluorescence reduction assay. To test this hypothesis, wild type and K304E MCAD were 
incubated with the synthetic peptide prior to the addition of native ETF in the enzyme assay, then 
the remainder of the assay was performed. One of the peptides, YAT191 was particularly 
effective in reducing the apparent MCAD activity, indicating that it interfered with the native 
ETF binding (Figure 27). 
         
Figure 27. ETF enzyme assay of the wild type and K304E MCAD with and without the wild type 
ETF docking site targeting peptide, YAT191 
 About 130nM of purified recombinant wild type and K304E MCAD proteins were co-incubated for 5 minutes with 
final 2.5mM of YAT191 peptide.  Then ETF reduction assay was performed to measure the MCAD activity. Assays 
were duplicated and average values were plotted. 
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A number of variations on wild type YAT191 were then synthesized and similarly tested 
searching for the ability to improve the inhibition of MCAD activity, which would imply 
stronger binding and more efficient protein stabilization. All of the peptides were able to 
interfere with interaction of ETF in this assay with maximum reduction to 20-30% of control 
activity (Figure 28). 
 
             
Figure 28. ETF enzyme assay of the wild type and K304E MCAD with and without ETF docking site 
targeting synthetic peptides (CCNFS, YRQF, YRQR, YAN, and YANF) 
About 130nM of purified recombinant wild type and K304E MCAD proteins were co-incubated for 5 minutes with 
2.5mM of each synthetic peptide.  The ETF reduction assay was then performed to measure the MCAD activity. 
Assays were duplicated and average values were plotted. 
  
To verity that these results were in fact due to interference with the binding of ETF to 
MCAD by the synthetic peptides, wild type and K304E MCAD activity was measured with the 
DCIP assay. This assay is based on colorimetric changes in the dye indicator and uses the small 
chemical electron acceptor PMS rather than ETF to reoxidize the enzyme in the second half 
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reaction. Thus, binding of a synthetic peptide to the ETF docking site would not be expected to 
affect the measured activity in this assay. This was in fact the case (Figure 29).  
 
                           
Figure 29. DCIP assay with wild type and K304E MCAD protein with and without added YAT191 
About 130nM of purified recombinant wild type and K304E MCAD proteins were co-incubated for 5 minutes with 
final 2.5mM of each synthetic peptide. Then DCIP colormetric assay was performed to measure the MCAD activity. 
Assays were duplicated and average values were plotted. 
 
3.4.3 ETF docking site targeting peptides increase the thermal stability of MCAD 
Interaction of native ETF with MCAD stabilizes both proteins. Thus, binding of the ETF 
docking site peptides were predicted to increase the thermal stability of the MCAD protein. To 
examine this hypothesis, wild type and mutant MCAD was tested for activity using the ETF 
fluorescence reduction assay at increasing temperatures with and without pre-incubation with the 
synthetic peptides. As expected, the K304E MCAD was less stable to thermal stress than wild 
type enzyme without the addition of the peptides (Figure 30).  
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Figure 30. The thermal stability of the purified recombinant wild type and K304E MCAD protein 
The recombinant wild type and mutant (K304E) were incubated at range of temperatures, at 2.5°C increments, for 5 
minutes each and measured for MCAD activity. Assays were duplicated and average values were plotted. 
 
Using the same approach, the change of MCAD activity at different temperatures in the 
presence of the ETF docking site targeting synthetic peptides was measured by the ETF assay. 
Figure 31 and figure 32 shows the changes of enzyme activity with various temperatures in the 
presence and absence of peptides, YATF, YRQF, YRQR, 194, 195, and 196. YRQR increased 
the thermal stability of the K304E MCAD. However, none of the other peptides showed 
significant increase in the thermal stability of the mutant MCAD, even though all of these 
peptides could reduce the activity of K304E MCAD in the ETF assay.  
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 Figure 31. The thermal stability of the bacterially purified K304E MCAD protein with ETF docking 
site targeting peptide (YATF, YRQR, and YRQF) 
The recombinant MCAD K304E was co-incubated with ETF docking site targeting peptide and then incubated at 
certain temperatures for 5 minutes and then MCAD K304E activity was measured. Assays were duplicated and 
average values were plotted. 
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Figure 32. The thermal stability of the bacterially purified wild type and K304E MCAD protein with 
or without 194, 195, or 196
The recombinant MCAD K304E was co-incubated with ETF docking site targeting peptides (194, 195, and 196) and 
then incubated at certain temperatures for 5 minutes and then MCAD K304E activity was measured. Assays were 
duplicated and average values were plotted. 
One of the peptides, YAT 193, with one amino acid change from the wild type peptide, 
significantly increased the thermal stability of the K304E MCAD activity (Figure 33).  
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Figure 33. Relative enzyme activity of K304E mutant MCAD in the presence and absence of peptides 
YAT191 and YAT193 at various temperatures 
The recombinant MCAD K304E was co-incubated with ETF docking site targeting peptide and then incubated at 
certain temperatures for 5 minutes and then MCAD K304E activity was measured. Assays were duplicated and 
average values were plotted. 
 
3.4.4 Binding of the YAT193 alters the structure of K304E MCAD as measured by CD 
spectroscopy 
To further examine the effect of the YAT 193 peptide K304E MCAD protein structure, 
the CD spectra of enzyme with and without peptide was determined. Co-incubation of YAT 193 
with the K304E MCAD protein led to significant changes in light polarization, consistent with a 
secondary structural change following binding of the peptide (Figure 34). These results support 
the observed increase in thermal stability.  
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 Figure 34. Effect on the recombinant K304E MCAD in the presence and absence of peptides YAT193 
by CD spectrum 
 The recombinant K304E MCAD protein and K304E MCAD co-incubated with YAT193 were incubated at certain 
temperature for 5 minutes and then measured by CD spectrometry. Readings at 445nm wavelength were graphed.  
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3.4.5 YAT193, ETF docking site targeting synthetic peptide, showed protective effect on 
the K304E MCAD protein from Staphylococcus aureus V8 
Mutant proteins often have a more open tertiary configuration compared to wild type 
counterparts due to subtle changes in protein folding. These changes in tertiary structure leave 
then more susceptible to digestion by cellular proteases, one mechanism for increased turnover 
rate of mutant proteins. In vitro, such changes can be demonstrated by treating mutant and wild 
type proteins with proteases under conditions leading to partial digestion, leading to more rapid 
degradation of a protein with an abnormal, more open configuration Therefore, I treated wild 
type and K304E MCAD for various times with endoproteinase Glu-C from Staphylococcus 
aureus V8 with and without pre-incubation with the ETF docking peptides. Staphylococcus 
aureus V8 can cut at glutamate residues, and the peptide pattern generated can be predicted from 
the amino acid sequence (Table 12). 
 
Table 12. Expected sizes of MCAD fragment by Staphylococcus aureus V8 protease 
Size MW pI Enzyme From:To Enzyme 
8 1032.11 10.99 N-terminus end 1:08 Staph-V8 
8 852.9 3.62 Staph-V8 9:16 Staph-V8 
3 395.4 3.62 Staph-V8 17:19 Staph-V8 
4 531.52 6.13 Staph-V8 20:23 Staph-V8 
11 1324.4 10.99 Staph-V8 24:34 Staph-V8 
1 147.13 3.62 Staph-V8 35:35 Staph-V8 
7 711.81 3.62 Staph-V8 36:42 Staph-V8 
6 711.66 4.12 Staph-V8 43:48 Staph-V8 
11 1399.6 9.05 Staph-V8 49:59 Staph-V8 
10 1124.27 5.14 Staph-V8 60:69 Staph-V8 
17 1669.78 3.32 Staph-V8 70:86 Staph-V8 
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1 147.13 3.62 Staph-V8 87:87 Staph-V8 
13 1325.43 3.62 Staph-V8 88:100 Staph-V8 
27 2991.22 9.41 Staph-V8 101:127 Staph-V8 
1 147.13 3.62 Staph-V8 128:128 Staph-V8 
10 1129.31 3.62 Staph-V8 129:138 Staph-V8 
15 1400.39 6.2 Staph-V8 139:153 Staph-V8 
5 575.52 6.2 Staph-V8 154:158 Staph-V8 
43 4844.18 9.22 Staph-V8 159:201 Staph-V8 
12 1284.33 6.21 Staph-V8 202:213 Staph-V8 
16 1825.99 6.21 Staph-V8 214:229 Staph-V8 
7 813.84 6.2 Staph-V8 230:236 Staph-V8 
38 3786.07 6.3 Staph-V8 237:274 Staph-V8 
7 794.82 6.13 Staph-V8 275:281 Staph-V8 
10 1190.32 9.81 Staph-V8 282:291 Staph-V8 
10 1146.27 5.14 Staph-V8 292:301 Staph-V8 
6 707.84 6.13 Staph-V8 302:307 Staph-V8 
12 1481.63 9.05 Staph-V8 308:319 Staph-V8 
41 4290.39 4.47 Staph-V8 320:360 Staph-V8 
4 506.54 3.62 Staph-V8 361:364 Staph-V8 
13 1670.83 8.63 Staph-V8 365:377 Staph-V8 
13 1470.62 10.09 Staph-V8 378:390 Staph-V8 
7 916.92 8.68 Staph-V8 391:397 COOH 
 
To optimize the protein visualization prior to proteolysis, different concentrations of 
purified recombinant K304E MCAD proteins were loaded onto 16.5 %T Tricine and 4-12 %T 
Tris SDS gels and stained with either Coomassie blue or silver staining following electrophoresis 
(Figure 35). Since silver staining can visualize smaller amount of proteins, silver staining in 
Tricine gel was used for the limited proteolysis experiment. 
 
 
Table 12 Continued 
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            (a)  M       25       20        15      10 (µg)            (b)  M     25      20     15     10 (µg)                      
 
(c) M        5        2.5        1      0.5 (µg)            (d)  M      5       2.5      1     0.5 (µg)                         
 
Figure 35. Staining of the recombinant K304E MCAD protein in different gel 
The recombinant K304E MCAD proteins were loaded 25, 20, 15, 10 µg for Coomassie staining and 5, 2.5, 1, 0.5 µg 
for silver staining. (a) Coommassie staining in 16.5 %T Tricine gel, (b) Coommassie staining in gradient 4-12 %T 
Tris gel, (c) silver staining in 16.5 %T Tricine gel, (d) silver staining in gradient 4-12 %T Tris gel. 
 
 
Figure 36 and figure 37 show results of a limited proteolysis experiment of K304E 
MCAD protein in the presence and absence of the YAT 191 and YAT 193 peptides, respectively. 
Panel (a) shows control proteolysis of the K304E MCAD protein and panel (b) shows the pattern 
of limited proteolysis in the presence of YAT 191 (Figure 36) and YAT 193 (Figure 37). Under 
the conditions used, proteolysis was rapid enough that even at the 0 time point (right after the 
addition of the V8 protease) digested fragments were visible. With increased protease incubation, 
additional cleavage bands appeared. The appearance of several of these bands was delayed 
following incubation with the docking peptides (most noticeable with the 12 kDa fragment 
labeled with the red arrow). To identify of these fragments, mass spectrometry was performed  
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(Figure 40), and its rate of appearance of this fragment was quantified by measuring the optical 
density of the fragment in proteolysis gels over several experiments (Figure 38 and 39). In the 
absence of YAT 191 in the digestion reaction, the appearance of the fragment plateaued at 7.5 
minutes. However, in the presence of YAT 191, the concentration of the fragment was increasing 
even at 30 minutes digestion, indicating resistance to digestion (Figure 38). When enzyme was 
pre-incubated with YAT 193, the 12 kDa fragment had also not peaked by 30 minutes of 
digestion (Figure 39). Note, that since relative gel staining was variable form one gel to the next, 
each graph was generated from the internal control included on that gel. 
 
 
(a) M      -       0     2.5     5     7.5    10     15    30  (b)M     -       0     2.5     5    7.5    10   15    30                
 
Figure 36. Limited proteolysis of the K304E MCAD protein with and without YAT191 
(a) K304E MCAD protein, (b) K304E MCAD protein with YAT191. The recombinant K304E MCAD protein was 
digested with V8 protease in the presence or absence of YAT191 peptide at different incubation time. Total 10 μg of 
the protein is loaded on each lane, electrophoresed in 16.5 %T Tricine gel, and stained with silver staining kit from 
Sigma. 
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(a) M     -       0     2.5     5      7.5    10     15    30 (b) M     -       0      2.5     5     7.5    10    15     30        
             
Figure 37. Limited proteolysis of the K304E MCAD protein with and without 193 
(a) K304E MCAD protein, (b) K304E MCAD protein with 193. The recombinant K304E MCAD protein was 
digested with V8 protease in the presence or absence of YAT193 peptide at different incubation time. Total 10 μg of 
the protein was loaded on each lane, electrophoresed in 16.5 % T Tricine gel, and stained with silver staining kit 
from Sigma. 
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  Incubation Time                0         2.5         5         7.5         10         15         30   
  MCAD (K304E)                              
  MCAD (K304E) + 191  
 
            
Figure 38. Limited proteolysis of K304E MCAD protein in the presence or absence of YAT191 
Recombinant K304E MCAD protein was treated with V8 protease in the presence or absence of YAT191 peptide 
and samples were withdrawn and reaction stooped at different incubation time. A total of 10 μg protein was loaded 
on each lane, electrophoresed in 16.5 %T Tricine gel, and stained with silver staining kit from Sigma. One of the 
proteolytic fragments, 12 kDa, was analyzed to investigate the relative density of the proteolysis product in the 
presence and absence of the YAT191. 
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  Incubation Time                  0         2.5       5        7.5      10       15        30   
  MCAD (K304E)                              
  MCAD (K304E) + 193  
              
Figure 39. Limited proteolysis of K304E MCAD protein in the presence or absence of YAT193 
The recombinant K304E MCAD protein was digested with V8 protease in the presence or absence of YAT193 
peptide at different incubation time. A total of 10 μg protein was loaded on each lane, electrophoresed in 16.5 %T 
Tricine gel, and stained with silver staining kit from Sigma. One of the proteolysis fragments, 12 kDa, was analyzed 
to investigate the relative density of the proteolytic product in the presence or absence of YAT193. 
 
 
3.4.6 MS/MS of a 12 kDa fragment of the K304E MCAD protein 
To further investigate the proteolytic products, one of the smallest fragments (about 12 
kDa) was analyzed by MS/MS. Figure 40 shows that the size and composition from the 
proteolysis fragment.  
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Figure 40. MS/MS results of limited proteolysed of K304E MCAD  
Selected V8 protease proteolysis K304E MCAD fragments were sent for MS/MS. 193-1 to 193-7 indicate different 
fragments from proteolysed K304E MCAD.  
 
Even though MS/MS confirmed that the generated fragments were MCAD protein 
fragments, we could not fine map the proteolysed pattern comparing to theoretic proteolysis 
estimation due to trypsin digestion in the MS/MS procedure (Table 8).  Since the analysis itself 
added additional digestion, it was difficult to compare these proteolytic fragments to estimated 
fragments and fine map the proteolysis pattern.  
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4.0  DISCUSSION 
4.1 SMALL CHEMICAL CHAPERONES AS A POTENTIAL TREATMENT 
FOR MCADD 
Previous studies with protein misfolding disorders have shown that small chemical 
chaperones can enhance proper folding of a mutant protein and stabilize its activity (Leandro and 
Gomes, 2008). As the result of a founder effect, ~90% of MCADD patients carry at least one 
copy of a K304E mutation that leads to the misfolding of the subunit following import into 
mitochondria, with subsequent degradation of the abnormal protein. The main hypothesis of this 
thesis was that small chemical chaperone can be used as a potential drug for MCADD by 
inducing proper folding of the K304E MCAD protein and/or stabilize already folded protein. 
 To test this hypothesis, MCAD activity was measured in lymphoblasts and fibroblasts 
from controls and patients homozygous for the common K304E mutation. MCAD activity in 
mutant cells was almost zero and was not improved by culture at low temperature as was 
observed in bacterial overexpression experiments (Bross et al., 1995). Of note, transcription of 
the mutant MCAD gene was the same as in wild type cells, and the MCAD antigen could be 
detected, consistent with a protein misfolding mechanism for loss of MCAD activity. Treatment 
of K304E MCAD mutant cells with the non-specific small chemical chaperones, TMAO and 
glycerol, partially rescued MCAD activity, and even increased activity in control cells, although 
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there was no effect on VLCAD activity in either cell line. These results provide proof-of-
principle that small chemical chaperones can significantly improve the K304E MCAD activity, 
substantiating its potential for drug development. The increase of normal MCAD protein in 
control cells following chaperone treatment suggests that this protein is inefficiently folded even 
under normal conditions, and that chaperone therapy may be more generally applicable to 
MCAD deficiency. Of course, glycerol and TMAO are not practical reagents to use in patients, 
and thus a compound more amenable to human therapy is required.  
Since about 90% MCADD patients have K304E mutation causing the failure of 
tetramerization, we hypothesized that small chemical chaperones can be used as a potential drug 
for MCADD by helping proper fold of the K304E MCAD protein.  
To test the hypothesis, the basal activity of the MCAD protein from control and patients’, 
homozygous for K304E MCAD, lymphoblasts was measured. Since K304E MCAD protein 
expression in bacteria showed the increased expression at low temperature and some misfolded 
proteins tend to be more stable at lower temperatures, lymphoblasts were also cultured at 30°C to 
test whether culturing at lower temperature can increase the K304E MCAD activity. The basal 
MCAD activity was almost zero in MCAD patients’ lymphoblasts and culturing at low 
temperature did not increase activity. Also there was no significant transcriptional change 
between control and K304E lymphoblasts. Therefore, we confirmed that the loss of MCAD 
activity in patients’ cells is not due to the mRNA expression.   
 Substrate binding pocket analogues are among the most effective chemical chaperones 
described in other enzyme systems. Since octanoate has neurotoxic effects, it is not a viable 
candidate for chaperone development. In contrast, sodium phenylbutyrate, an FDA approved 
medication for treatment for urea cycle disorders, is well tolerated at supra-physiologic 
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concentrations compared to octanoate. Phenylbutyrate is activated to phenylbutyryl-CoA, which 
undergoes one round of β-oxidation initiated by MCAD as shown in this thesis. Thus 
phenylbutyryl-CoA was hypothesized to accumulate in MCAD deficient cells containing at least 
one copy of the K304E mutation, bind to folding mutant enzyme, and promote stability of the 
abnormal enzyme. To examine this hypothesis, phenylbutyryl-CoA was first shown to increase 
the thermal stability of K304E MCAD in an in vitro assay. Its ability to increased MCAD 
activity was then tested in fibroblasts and lymphoblasts from patients homozygous for the 
common mutation. These experiments unequivocally confirmed that the K304E MCAD was 
stabilized in phenylbutyrate treated cells. However the final activity was low enough to make 
accurate quantitation difficult. To overcome this issue, a HEK293 cell line with inducible wild 
type or K304E MCAD vectors were used to boost MCAD expression for improved detection. 
These experiments showed a consistent increase in K304E MCAD activity following treatment 
with 0.5 mM PBA, while MCAD gene expression remained constant. These results are 
promising proof-of-principle for a clinical trial in MCAD patients since identification of mild 
deficiencies through newborn screening programs has led to the suggestion that even a small 
amount of MCAD activity is sufficient to protect against metabolic decompensation. Based on 
these findings, a limited clinical trial has already been started at Children’s Hospital of 
Pittsburgh to treat patients homozygous for the K304E MCAD allele with sodium 
phenylbutyrate.  
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4.2 INVESTIGATING ALTERNATIVE SITES FOR DRUG TARGETING IN 
MCADD  
As with substrate binding to their binding pockets, binding of ligands to other sites on a 
protein can serve to stabilize it. To identify additional potential “drugable” sites for K304E 
MCAD, the mutant was expressed it in E. coli, purified to essential homogeneity, and was 
provided it to a collaborator to determine its X-ray crystal structure. The protein structural 
modeling showed that there were only minor differences in the trajectory of some surface loops 
between wild type and K304E MCAD protein structure. The three dimensional structure now 
provides an opportunity to identify targets for development of pharmacologic chaperones for 
treatment of MCAD deficiency. One such option is the core of the MCAD tetramer where the 
K304E mutation lies (Figure 41).  
                       
Figure 41. Ribbon representation of the crystal structure of the MCAD tetramer core 
The four monomeric MCAD subunits are shown. The tetrameric core is located in the middle.   
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 Another site for drug targeting is the interface between ETF and MCAD. The structure of 
this complex has previously been determined through X-ray crystallography and examination of 
published model allowed the design of 12 amino acid peptides predicted to bind to ETF docking 
site. Since the interaction of ETF and MCAD stabilizes these proteins, binding of peptides to the 
MCAD:ETF docking site were predicted to increase the stability of MCAD. Enzymatic analysis 
of MCAD incubated with ETF docking site peptides confirmed that they were bound to the 
enzyme and interfered with subsequent interaction of native ETF with MCAD. To examine the 
effect of synthetic ETF docking peptides on MCAD stability, K304E MCAD was incubated at 
increasing temperatures with selected synthetic peptides and the MCAD activity and circular 
dichroism were monitored. One of the 12-mer ETF docking site peptides, YAT193, increased the 
thermal stability. Limited proteolysis experiments confirmed its effect on stability, showing 
reduced rate of proteolysis of the K304E MCAD protein after incubation with the YAT193 
peptide.   
 These results identify the MCAD:ETF docking site as a candidate pharmacophoric site 
for MCADD drug development. Generation of clinically applicable drugs will require 
modification of the synthetic peptide structure using structure-based drug design. This process 
will be greatly enhanced by the having the crystal structure of K304E MCAD now available. Co-
crystalization of K304E MCAD protein and the YAT193 peptide will allow better 
characterization of the atomic forces driving this interaction and allow the use of YAT193 as a 
scaffold for more appropriate molecules for physiologic use. Also, in silico library screening can 
be used to examine other drug-like compounds to identify those with the potential to bind to the 
ETF docking site or use a fragment-based drug design approach.  
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 An additional benefit of the experiment in this thesis is the potential for development of 
medications to treat other ACAD deficiencies. The other ACADs are highly homologous to 
MCAD (Figure 42), and the x-ray crystal structure of many of them has been determined. 
Lessons learned in this thesis thus provide a starting point for similar attempts for the other 
enzymes.  
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Figure 42. Amino acid sequence alignment of ACADs. 
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 4.3 DEVELOPMENT OF HIGH-THROUGHPUT ASSAY FOR MCAD 
FUNCTION AND DRUG SCREENING 
Experiments in this thesis were possible because only a small number of potential 
chaperones identified on the basis of the known enzyme structure were examined. While this is a 
viable alternative for potential drug-binding sites, the development of a high-throughput assay 
system would be beneficial to identify candidate chemical chaperones for MCAD and other 
ACADs in more extensive chemical libraries. To this end, a high-throughput assay for MCADD 
based on imaging of immunostained cells in 384 well microtiter plates using a highly automated 
robotic platform was attempted. After what seems to be initial success, later results were 
inconsistent showing no significant difference in immunologic signal between wild type and 
fibroblasts homozygous for the K304E mutation. Previous literature reports were conflicting as 
to the relative stability of MCAD antigen in such cells, with some publications showing near 
normal levels of the antigen in K304E mutant cells, while others report little or no mutant 
protein. However, the discrepancy seems to be related to cell passage number, which seems to 
affect mitochondrial content of wild type and patient cells. It is also possible that some 
undescribed variation in culture or staining conditions account for this discrepancy, and future 
attempts at developing an antigen-based assay will need to further explore these factors.  
Another possibility for a high-throughput assay is to test directly for MCAD activity. The 
ETF fluorescence reduction assay used throughout this thesis is highly sensitive, reliable, and 
highly specific for the ACADs, and demonstrates complete lack of activity in cells homozygous 
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for the K304E mutation. Thus adaptation of this assay to 96 microtiter plates would allow ready 
screening of chemical libraries for chaperone function. Unfortunately there are some 
experimental limitations to the adaptation of this assay to higher throughput technology, 
including problems related to robotic processing of cellular extracts.  
4.4 FUTURE DIRECTIONS 
 
This study showed two approaches to investigate the development of MCADD therapy: 
first, the use of small chemical chaperones as drugs and second, and investigation of an MCAD 
drug targeting site. Since the common K304E MCAD mutation results in protein misfolding 
leading loss-of-function of the MCAD protein, recovery of this mutant MCAD activity is the key 
to overcome this condition. This study provided the proof-of-principle that the use of small 
chemical chaperone can increase the K304E MCAD activity. Also, by targeting ligand-binding 
site of the K304E MCAD protein, the stabilization and increase in activity in K304E MCAD 
protein are possible.  
There can be other approaches to improve the mutant MCAD activity whether it is a 
common mutation having K304E or any other mutations. Hepatocyte transplantation (HTx) has 
been used as a bridging therapy for some inborn errors of metabolism disorders especially those 
are involved in liver. We can apply hepatocyte transplantation as a therapy for MCADD. To 
investigate whether HTx can be a doable therapy for MCADD, first, we can use a MCAD knock-
out (KO) mice model, which is available, to test the HTx for MCADD treatment. Hepatocytes 
from wild type mice can be directly injected into the liver pulp of neonatal MCAD KO mice. The 
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utility of HTx can be evaluated by MCAD enzyme activity, composition of metabolites before 
and after the transplantation, and fasting and cold challenge of these mice. If this can be 
validated from MCAD KO mice model we can apply this method into MCADD patients. The 
limitations of this method can be the side effects of immune response and lack of the sources of 
wild type hepatocyte. The use of induced pluripotent stem (iPS) cells from the patients could 
overcome these limitations since the sources of wild-type hepatocytes are from the same patients 
but gene correction would be required before the generation of hepatocytes.   
 
4.5 PUBLIC HEALTH IMPORTANCE OF THIS STUDY 
MCADD is the most common inborn error of metabolism identified by tandem mass 
spectrometry in the United States, affect ~1:16,000 babies. Before the era of NBS, about 20 to 
25% of the MCADD patients either died in early childhood or developed serious disabilities as a 
result of an acute metabolic episode (Grosse et al., 2006). With universal NBS in the United 
States, affected individuals are detected easily, and proper care prevents acute and severe adverse 
outcomes. However, multiple problems still exist relating to the proper management of MCADD 
(Schatz and Ensenauer, 2010). First, clinical manifestations of MCADD remain a considerable 
problem, especially in children age 3 to 24 months. This counters the common perception that 
MCADD is effectively treated by diet. Emergency care with hospitalization at clinical onset is 
required in as high as 95% of MCADD patients (Iafolla et al., 1994). Manifestations of MCADD 
occur in both children and adults even after the common adoption of NBS (Schatz and 
Ensenauer, 2010), and poor outcomes of MCADD in adolescence and young adults have also 
 88 
been reported (Mayell et al., 2007; Wilhelm, 2006; Yusupov et al., 2010). Under the best of 
circumstances, careful monitoring of frequent food intake when ill is critical. Also, there are no 
set clinical standards for fasting tolerance even in well children. One study suggests a maximum 
duration of fasting in children with MCADD of 8 hours for the ages of 6 months to 1 year of age, 
10 hours for the second year of life, and 12 hours, thereafter, but no global consensus exists 
(Derks et al., 2007). Also, many studies tried to investigate genotype-phenotype relationship for 
mutations in MCADD (Andresen et al., 2001; Andresen et al., 2012; Gregersen et al., 2001; Leal 
et al., 2013; Waddell et al., 2006). However, it remains contentious. Even though about 90% of 
patients have at least one 985A>G allele, other mutations or combinations with the 985A>G 
allele have not been carefully studied yet. Recently, Touw et al. tried to set a guideline to help 
the patients by comparing MCAD activity between in vitro and in vivo and data analysis from a 
cohort study (Touw et al., 2012; Touw et al., 2013). However, these cannot be applied clinically 
due to possible unexpected physiological stress or any other emergent metabolic episodes. These 
present difficulty when advising patients of the risk for episodes of metabolic decompensation 
and how to properly manage their condition. Current treatment options are frequent food intake, 
restriction in long-chain fatty acid intake, and cofactor supplementation (Vockley and Whiteman, 
2002). IV glucose for metabolic episodes is needed. In total, these issues identify a need for a 
better therapy for MCADD. Development of a pharmacologic treatment for MCADD will 
eliminate the risk or metabolic decompensation and improve the lives for affected patients.  
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4.6 CONCLUSIONS 
In conclusion, these results in these studies demonstrate that small chemical chaperones 
can increase the K304E mutant MCAD enzyme activity in vivo.  The CoA ester substrate binding 
and the ETF docking sites are suitable targets for drug development. Phenylbutyrate, an FDA 
approved drug for treatment of the urea cycle, rescues K304E MCAD activity and thus 
represents a viable medication to test through clinical trials. Determination of the X-ray crystal 
structure of the K304E MCAD will allow identification of additional motifs to target for drug 
design. Development of a drug treatment for MCAD deficiency will provide significant benefits 
to patients with this disorder and their families.  
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5.0  EVIDENCE FOR INVOLVEMENT OF MEDIUM CHAIN ACYL-COA 
DEHYDROGENASE IN THE METABOLISM OF PHENYLBUTYRATE 
This work has been previously published (Kormanik et al., 2012) and is also included in 
the PhD thesis of Kaitlyn Kormanik. My role in the study included expression and purification of 
the recombinant MCAD, participation in design and analysis of enzymatic experiments, and 
participating in the preparation of the manuscript for publication. Copyright permission was 
obtained to include the manuscript in this thesis dissertation.  
Kormanik K, Kang H, Cuebas D, Vockley J, Mohsen AW. (2012) Evidence for involvement of 
medium chain acyl-CoA dehydrogenase in the metabolism of phenylbutyrate.  Mol. Genet. 
Met. 107(4):684-9. 
5.1 ABSTRACT 
Sodium phenylbutyrate is used for treating urea cycle disorders, providing an alternative 
for ammonia excretion. Following conversion to its CoA ester, phenylbutyryl-CoA is postulated 
to undergo one round of β-oxidation to phenylacetyl-CoA, the active metabolite. Molecular 
modeling suggests that medium chain acyl-CoA dehydrogenase (MCAD; EC 1.3.99.3), a key 
enzyme in straight chain fatty acid β-oxidation, could utilize phenylbutyryl-CoA as substrate. 
Moreover, phenylpriopionyl-CoA has been shown to be a substrate for MCAD and its 
intermediates accumulate in patients with MCAD deficiency. We have examined the 
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involvement of MCAD and other acyl-CoA dehydrogenase (ACADs) in the metabolism of 
phenylbutyryl-CoA. Anaerobic titration of purified recombinant human MCAD with 
phenylbutyryl-CoA caused changes in the MCAD spectrum that are similar to those induced by 
octanoyl-CoA, its bona fide substrate, and unique to the development of the charge transfer 
ternary complex. The calculated apparent dissociationconstant (KD app) for these substrates was 
2.16 μM and 0.12 μM, respectively. The MCAD reductive and oxidative half reactions were 
monitored using the electron transfer flavoprotein (ETF) fluorescence reduction assay. The 
catalytic efficiency and the Km for phenylbutyryl-CoA were 0.2 mM-1⋅ sec-1 and 5.3 μM 
compared to 4.0 mM-1⋅ sec-1 and 2.8 μM for octanoyl-CoA. Extracts of wild type and MCAD-
deficient lymphoblast cells were tested for the ability to reduce ETF using phenylbutyryl-CoA as 
substrate. While ETF reduction activity was detected in extracts of wild type cells, it was 
undetectable in extracts of cells deficient in MCAD. The results are consistent with MCAD 
playing a key role in phenylbutyrate metabolism. 
5.2 INTRODUCTION  
Impairment of urea synthesis in humans is caused by defects in the activity of enzymes in 
the urea cycle including carbamylphosphate synthetase, ornithine transcarbamylase, 
argininosuccinic acid synthetase, argininosucinate lyase, and arginase and leads to 
hyperammonemia. High levels of ammonia in blood may lead to encephalopathy and death 
(Foundation, 2005). Sodium phenylbutyrate is the active ingredient in Buphenyl ® (Corporation, 
2005-2006)  and is currently used for treating primary hyperammonemia caused by certain urea 
cycle defects (Pharmaceutical, 2005-2006). Sodium phenylbutyrate may also be useful in 
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treating secondary hyperammonemia that accompanies other inborn errors. In addition, 
phenylbutyrate has been and is being investigated in numerous clinical settings including 
modulation of fetal hemoglobin gene expression in sickle cell and in thalassemia, treatment of 
myleodysplastic syndromes and acute myeloid leukemia, cerebral and liver ischemic injury 
protection, among others (Egger et al., 2007; Gore et al., 2001; Saito et al., 2009; Vilatoba et al., 
2005). As of this writing >30 trials involving sodium phenylbutyrate are listed on the 
www.clinicaltrial.gov website.  The mechanism proposed for ammonia clearance by 
phenylbutyrate administration involves its activation to phenylbutyryl-CoA, conversion to 
phenylacetyl-CoA, and conjugation with glutamine (Figure 43) for excretion by the kidneys (Qi 
et al., 2004).  
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Figure 43. Metabolism of phenylbutyrate to its final metabolite 
 
The conversion of phenylbutyryl-CoA to phenylacetyl-CoA is presumed to occur through 
one cycle of β-oxidation in mitochondria. The first step in the β-oxidation cycle is the α,β-
dehydrogenation of fatty acid CoA esters catalyzed by members of the acyl-CoA dehydrogenase 
(ACAD) family of enzymes. Nine members of this enzyme family have been identified, each 
with characteristic substrate specificity profile (Ikeda et al., 1983; Ikeda et al., 1985b; Ikeda and 
Tanaka, 1983; Izai et al., 1992; Nguyen et al., 2002; Rozen et al., 1994; Willard et al., 1996; 
Zhang et al., 2002). Short, medium, long, saturated very long, unsaturated very long chain acyl-
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CoA dehydrogenases (SCAD, MCAD, LCAD, VLCAD and ACAD9) have substrate optima of 
C4, C8, C12, C16, and C16:1 (unsaturated very long chain among others) acyl-CoA esters, 
respectively, but can utilize other substrates (Ensenauer et al., 2005a; Ikeda et al., 1983; Ikeda et 
al., 1985a; Ikeda et al., 1985c). The crystal structures of SCAD, MCAD, and VLCAD have been 
published, (PDB ID: 1JQI, 3MDE, and 43B96, respectively) (Battaile et al., 2002; Kim et al., 
1993; McAndrew et al., 2008). The remaining four enzymes in the family are involved in amino 
acid metabolism and their crystal structures have been published as well, (PDB ID: 1IVH, 1SIR, 
1RX0, and 2JIF) revealing relatively restrictive active sites, rendering them highly specific for 
their bona fide substrates (Battaile et al., 2004; Fu et al., 2004; Tiffany et al., 1997). 
It has been observed that patients with MCAD deficiency characteristically accumulate 
both the glycine and carnitine conjugates of phenylpropionate, a bacterial metabolite from bowel 
flora that is absorbed into the blood stream (Rinaldo et al., 1988). Mass spectrometry based 
enzymatic assay of MCAD deficient patient fibroblast cells using phenylpropionyl-CoA as 
substrate showed lack of conversion to its α,β-unsaturated product (Derks et al., 2008). While the 
crystal structure of SCAD and VLCAD and homology 3D modeling of ACAD9 show that the 
active site would not accommodate the phenylbutyryl acyl moiety, the active site of MCAD 
would. These findings and the structural similarities between phenylpropionate and 
phenylbutyrate implicate MCAD in the metabolism of phenylbutyryl-CoA.  In this study we 
tested the ability of purified human recombinant ACADs to bind and use phenylbutyryl-CoA as a 
substrate. We demonstrate that MCAD indeed uniquely utilizes phenylbutyryl-CoA as a 
substrate. In addition, we show the inability of extracts prepared from MCAD-deficient 
fibroblast to act upon this substrate.  
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5.3 MATERIALS AND METHODS 
5.3.1 Purification of recombinant human MCAD 
Expression and purification of recombinant human MCAD was performed as previously 
described for isovaleryl-CoA dehydrogenase with minor modifications (Mohsen and Vockley, 
1995). E. coli JM105 cells (Amersham Biosciences Corp; Piscataway, NJ) containing the human 
MCAD high expression vector pKeMCAD (Matsubara et al., 1989) and a GroEL/GroES 
expression plasmid were grown overnight in a 200-ml LB broth pre-culture that was used to 
inoculate 4 x 2-L cultures in 2-YT broth. The cells were left to grow overnight at 37˚C with 
shaking and MCAD expression was induced the next morning using IPTG at a final 
concentration of 0.5 mM for 3 hrs. Cells were harvested by centrifugation and resuspended in 2:1 
weight to volume of 100 mM potassium phosphate pH 8.0, 150 mM EDTA. Cells were then lysed 
by sonication on ice. Including high amounts of EDTA in the cell lysis buffer is for protecting 
residues with groups, e.g., cysteine thiols and methionine sulfide groups, vulnerable to 
modification by oxygen reactive species generated during sonication cell suspension. This was 
effective in improving enzyme preparations resulting higher specific activity and consistent 
kinetic behavior (A-W Mohsen, 1999). Cellular debris was removed by centrifugation at 250,000 
x g for 60 minutes. The final supernatant was dialyzed for 4 hours with vigorous stirring in 50 
mM potassium phosphate pH 8.0, at 4˚C. The sample was then loaded on a 16 x 40 mm DEAE 
Sepharose FF column preequilibrated in 50 mM potassium phosphate pH 8.0, using an ÄKTA 
UPC-900 pump FPLC system (Amersham Biosciences Corp; Piscataway, NJ). After washing 
with 300 ml of 50 mM potassium phosphate pH 8.0, MCAD was eluted with a 300 ml linear 
gradient from 50 to 500 mM potassium phosphate pH 8.0. Green fractions with a 270/447 nm 
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ratio <12 containing MCAD were pooled, concentrated, and dialyzed against 25 mM potassium 
phosphate, pH 8.0. Pooled fractions of essentially pure MCAD (270/447 nm ratio = 5.5), were 
concentrated and stored at –80˚C. Other recombinant human ACADs were similarly purified 
except that the protocol was terminated after the DEAE-Sepharose column for LCAD as the 
enzyme was unstable. LCAD protein purity ~70% at this stage. 
5.3.2 The electron transfer flavoprotein (ETF) purification 
Porcine ETF was purified as previously published (Vockley et al., 2000), except that the 
dialysis buffer used after both the 40-60% ammonium sulfate fractionation and DE-52 cellulose 
anion-exchange chromatography steps consisted of unbuffered 15 mM dibasic potassium 
phosphate and 5% glycerol. 
5.3.3 Fibroblast cell culture and extract preparation 
Wild type and MCAD deficient cells (homozygous for the K304E mutation) with the 
designation GM085401 and GM07844, respectively, were obtained from Coriell Institute for 
Medical Research, Camden, NJ. Cells were cultured in DMEM medium supplemented with 
glutamine and ampicillin and streptomycin, and 20% fetal bovine serum. Cells were harvested 
from a T175 flask by sonication with a buffer consisting of 50 mM Tris buffer and 10 mM 
EDTA, pH 8.0. The cell debris was removed by centrifugation and the cell free extract was 
assayed for protein and enzyme activity as described below. 
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5.3.4 ETF fluorescence reduction assay 
The ETF reduction assay was performed using a Jasco FP-6300 spectrofluorometer 
(Easton, MD) with a cuvette holder heated with circulating water at 32˚C. The assay was 
otherwise performed as described (Frerman and Goodman, 1985), at the indicated substrate 
concentrations. The enzyme was diluted 1200-fold into a buffer containing 50 mM Tris, pH 8.0, 
5 mM EDTA and 50% glycerol, and 10 μl were used for each assay. The ETF concentration in 
the reaction mixture was 2 μM. Spectra Manager 2 software (Jasco Inc) was used to collect data 
and calculate reaction rate and Microsoft Excel was used to calculate the kinetic parameters. 
5.3.5 Phenylbutyryl-CoA synthesis 
CoASH, octanoyl-CoA, C12-CoA and phenylbutyric acid were obtained from Sigma (St. 
Louis, MO) 2,6-dimethylheptanoic acid was obtained from Matreya LLC (Pleasant Gap, PA). 
The phenylbutyryl-CoA and 2,6-dimethylheptanoyl-CoA esters were prepared by the mixed 
anhydride method as described previously (Schulz, 1974) and was purified by HPLC using a 
Luna 5 μm C18(2) column (25 cm x 0.46 cm) and a linear gradient (10-60%) of acetonitrile into 
50 mM ammonium phosphate, pH 5.5, at a flow rate of 1.5 mL/min over 30 min. 
5.3.6 Monitoring the interaction of MCAD with substrates 
Formation of the charge transfer ternary complex was monitored by observing the 
increase in absorbance at the 570 nm area, concomitant with the decrease of absorbance at 447 
nm area, of the purified MCAD in 120 mM potassium phosphate spectrum under anaerobic 
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conditions using a JascoV-650 Spectrophotometer. Phenylbutyryl-CoA solution dissolved in 
water to 0.53 mM was titrated into the MCAD sample one μL at a time using a 50 μl Hamilton 
syringe attached to an automatic dispenser. Ten seconds of equilibration time were allowed after 
mixing before the sample was scanned at 250 to 800 nm. Final substrate concentrations varied as 
indicated in figure legends. All data were adjusted for the dilution resulting from substrate 
addition. Substrates were titrated, but with different final concentrations as indicated in the figure 
legends. The dissociation constant (KD app) was calculated with the Stockell equation as described 
previously (McKean et al., 1979): 
                                
where d is the total ligand concentration, e is the total molar concentration of enzyme, p is the 
fraction of enzyme sites that bind ligand multiplied by e, and n is the number of binding sites. 
The absorbance at 447 nm when all enzyme sites are occupied with ligand was determined 
separately by adding large excess of octanoyl-CoA and used to calculate the fraction of enzyme 
with bound ligand at various readings and assuming that at large excess of added substrate would 
equal to e. 
5.3.7 Molecular modeling 
Computer modeling of MCAD was performed using a Silicon Graphics Fuel workstation 
(Mountain View, CA) with the Insight II 2005 software package and MOE software, from 
Chemical Computing Group, Montreal, Canada, and the atomic coordinates of pig MCAD 
(3MDE) in the dimer form as a molecule (Kim et al., 1993). Carbon atoms at positions C5-C8 of 
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the octanoyl-CoA ligand, which co-crystallized with MCAD, were replaced with a phenyl group. 
The phenylbutyryl-CoA ligand conformation in the active site was refined using the Discover 
module. Human LCAD 3D structure was modeled using MCAD atomic coordinates as template 
and the Insight II modeling software. 
5.4 RESULTS 
5.4.1 Interaction of MCAD with substrates, the reductive half-reaction 
Formation of the charge transfer complex, the reductive half-reaction, is evident from the 
spectral scans of MCAD at various phenylbutyryl-CoA concentrations (Figure 44 and 45).  
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 Figure 44. Monitoring the formation of the charge transfer complex with purified MCAD upon 
addition of increasing amounts of octanoyl-CoA 
 
The absorbance maxima at ~370 nm and ~447 nm are reduced and a new peak centered at 570 nm appears with 
addition of increasing substrate. Selected scans are shown with octanoyl-CoA concentration at 0, 3.25, 7.1, 10.8, 
15.6, 18.0, 21.5, and 28.2 μM. The inset shows the kinetics of these changes. Equation for the decrease at 447 nm is: 
y = –1 x 10-9x6 + 1 x 10-7x5 – 2 x 10-6x4 + 2 x 10-5x3 – 0.0003x2 – 0.008x + 0.3489. Equation for the increase at 570 
nm is: y = 6 x 10-10 x6 – 5 x 10-8 x5 + 1 x 10-6 x4 – 2 x 10-5 x3 + 0.0003x2 + 0.0003x + 0.0008. Enzyme concentration 
was 25.2 μM. 
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 Figure 45. Monitoring the formation of the charge transfer complex with purified MCAD upon 
addition of increasing amounts of phenylbutyryl-CoA 
The absorbance maxima at ~370 nm and ~447 nm are reduced and a new peak centered at ~570 nm appears with 
addition of increasing substrate. Selected scans are shown with phenylbutyryl-CoA concentration at 0, 4.2, 8.3, 16.3, 
24.1, 31.6, 40.7, and 80.2 μM. The inset shows the kinetics of these changes. Equation for the decrease at 447 nm is: 
y = 5 x 10-10 x5 – 1 x 10-7 x4 + 9 x 10-6 x3 – 0.0002 x2 – 0.0061 x + 0.3707. Equation for the increase at 570 nm is: y = 
– 1 x 10-10 x5 + 3 x 10-8 x4 – 3 x 10-6 x3 + 7 x 10-5 x2 + 0.0012 x + 0.0036. Enzyme concentration was 25.2 μM. 
 
The progressive decrease and increase of absorbance at 447 nm and 570 nm, respectively, 
are similar to those induced by octanoyl-CoA. The octanoyl-CoA binding curve is sigmoidal in 
contrast to the phenylbutyryl-CoA binding curve, possibly reflecting differences in enzyme 
mechanism of interaction. The plot of d/p versus 1/e-p (the Stockell plot) was nonlinear. A line 
drawn at the straight area of the curve where the substrate:subunit ratio was 1:1 estimates the 
apparent dissociation constant (KD app) being 0.12 μM and 2.16 μM for octanoyl-CoA and 
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phenylbutyryl-CoA, respectively. Other mathematical derivatives of the absorbance data all 
indicated that the binding sites are non-equivalent. 
 
Table 13. Kinetic Constants of Recombinant Human MCAD Using Octanoyl-CoA and 
Phenylbutyryl-CoA as Substrates and the ETF Fluorescence Reduction Assay 
 
5.4.2 Interaction of MCAD: Substrate ternary complex with ETF, the oxidative half 
reaction 
Using ETF as the electron acceptor in the standard enzymatic assay detailed above, 
transfer of electrons was confirmed as evident from the reduction of ETF fluorescence in the 
presence of various concentrations of phenylbutyryl-CoA. The catalytic efficiency and Km for the 
phenylbutyryl-CoA were 0.2 mM-1⋅ sec-1 and 5.3 μM compared to 4.0 mM-1⋅ sec-1 and 2.8 μM for 
octanoyl-CoA, respectively. 
 
Molecular modeling of human LCAD shows possible accommodation of the acyl moiety 
of the phenylbutyryl-CoA, with the exception of residue L264, which would have one of its side 
chain methyl hydrogens ~1.3Å away from a phenyl ring hydrogen and so would hinder binding. 
To test if the LCAD active site has enough plasticity to accommodate this potential substrate, we 
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measured its activity with LCAD using the ETF fluorescence reduction assay. While the partially 
purified recombinant human LCAD was active in the presence of various substrates including 
C12-CoA and 2,6-dimethylheptanoyl-CoA, it was not active in the presence of phenylbutyryl-
CoA. Purified SCAD, MCAD, and ACAD9 also showed no activity with phenylbutyryl-CoA as 
substrate. 
5.4.3 The ETF fluorescence reduction assay of cell extract 
ETF fluorescence reduction was observed using extracts from wild type fibroblast cells in 
the presence of 30 μM of phenylbutyryl-CoA, octanoyl-CoA, or palmitoyl-CoA. (The latter 
substrate was used as internal control and is a substrate of VLCAD.) Enzyme specific activity 
measured using these substrates was 3.41 (0.53), 4.01 (1.34), 9.10 (2.13) nmoles ETF reduced⋅ 
min-1⋅ mg-1, respectively. No activity was observed using similar amounts of extract from 
fibroblast cells deficient in MCAD with either phenylbutyryl-CoA or octanoyl-CoA. The 
measured enzyme specific activity of palmitoyl-CoA oxidation in extract from these cells was 
3.91 (1.34) nmoles ETF reduced⋅ min-1⋅ mg-1. 
5.5 DISCUSSION 
Following the conversion of phenylbutyrate to the CoA ester, one cycle of β-oxidation is 
expected to result in phenylacetyl-CoA and acetyl-CoA as the final products (Figure 46).  
Phenylacetyl-CoA is hydrolyzed to phenylacetate, which becomes conjugated with glutamine 
and is excreted in urine (Figure 43). An analysis of this first step in the β-oxidation of 
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phenylbutyryl-CoA is important because the first step in the β-oxidation of fatty acids is 
postulated to be rate-limiting (P Macheroux, 1997), and thus the metabolism of Buphenyl to its 
active form, phenylacetate, may also be modulated by similar factors that affects energy 
metabolism at the same step.   
The effect of phenylbutyryl-CoA on the MCAD absorbance spectrum at relatively low 
concentrations is monitored via the decrease of absorbance at 447 nm and increase of absorbance 
at 570 nm. This confirms productive binding of phenylbutyryl-CoA to MCAD in the reductive 
half reaction with lack of product release. This effect is similar to that induced by octanoyl-CoA 
binding to MCAD, and indicative of the transfer of a proton and a hydride to the flavin ring and 
formation of the charge transfer complex, which is comprised of the enzyme, reduced FAD, and 
enoyl product and detected by the intense absorbance band centered at 570 nm (Ghisla and 
Thorpe, 2004; Lau and Thorpe, 1988). 
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 Figure 46. Detailed proposed pathway of metabolism of phenylbutyrate to its active form, 
phenylacetate 
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The inset in Figure 44 shows a sigmoidal shaped curve when octanoyl-CoA, but not 
phenylbutyryl-CoA, was used as substrate. This may imply positive cooperativity between the 
first and second subunits with octanoyl-CoA binding that does not occur with phenylbutyryl-
CoA.  Although other interpretations of sigmoidal behavior in this setting are possible, including 
presence of various MCAD forms or other effector molecules, the argument is weakened by the 
fact that the only difference between the two reactions is the substrate itself. Impurities in the 
substrate preparation are also not likely to induce such an effect as such impurities would be 
present at ineffectively low concentrations at the low substrate concentrations range, between 
0.25-1 and 4:1substrate:MCAD tetramer ratio. 
Reduction of ETF by the charge transfer complex in the oxidative half-reaction shows 
that electrons from the bound phenylbutyryl-CoA can be efficiently transferred to ETF and that 
the product, phenylbutenoyl-CoA, is released to complete the reaction. In contrast, none of the 
other ACADs are capable of catalyzing this reaction. 
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 Figure 47. Stick representation of MCAD active site residues and ligands with phenylbutyryl-CoA 
modeled in place of octanoyl-CoA 
The crystal structure of pig MCAD with bound octanoyl-CoA (PDB: 3MDE, [20]) was used to create the model 
using MOE modeling software. The E376 carboxylate is the active site catalytic base responsible for the substrate 
C2 proton abstraction to initiate catalysis. 
 
Modeling of a phenylbutyryl moiety in the active site in place of the octanoyl moiety 
observed in the MCAD crystal structure shows the phenyl moiety accommodated in the acyl 
moiety binding site pocket with a conformation perpendicular to the aromatic ring of Y375, 
Figure 47. Other residues involved in binding the phenyl moiety include E99, A100, Leu103, and 
V259. Furthermore, modeling predicts that the phenyl ring para and/or meta positions are 
candidate expansion sites for adding a functional group that may improve binding, while addition 
at the ortho position would prevent the derivative from binding to MCAD. 
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Based on the kinetic parameters of MCAD with phenylbutyryl-CoA as substrate, 
individuals with MCAD deficiency are likely to experience a functionally relevant decrease in 
the ability to metabolize the medication, though indications for use in these patients are likely to 
be rare. Of note, since octanoyl-CoA has been reported to provide thermal stability to the MCAD 
K304E mutant (Nasser et al., 2004), it is possible that phenylbutyryl-CoA would behave 
similarly and may be of benefit in vivo in patients carrying at least one copy of this mutation. 
This requires additional investigation in cellular or whole body systems. It is unknown if carriers 
for MCAD deficiency, a much more common situation, will display altered metabolism of 
phenylbutyrate. In other indications where the functional effects of phenylbutyrate are less well 
characterized, modulation of MCAD activity might be of benefit to alter drug metabolism and/or 
its half-life and increase its efficacy, depending on the mechanism of action of the medication in 
each disorder. Detailed biochemical studies to determine the drug’s mode of action and its 
pharmacokinetics for such indications are thus crucial. 
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